Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 20321. Отображено 100.
09-02-2012 дата публикации

Charge transport compositions and electronic devices made with such compositions

Номер: US20120032158A1
Принадлежит: EI Du Pont de Nemours and Co

The present invention is directed to a photoactive device comprising an anode, a cathode, and a photoactive layer, which device further comprises an electron transport and/or anti-quenching layer which minimizes both electron transfer quenching and energy transfer quenching of the photoactive layer.

Подробнее
15-03-2012 дата публикации

Electroactive materials

Номер: US20120065432A1
Принадлежит: EI Du Pont de Nemours and Co

A compound having Formula I, Formula II, or Formula III: Ar 1 may independently be phenylene, substituted phenylene, naphthylene, or substituted naphthylene. Ar 2 is the same or different at each occurrence and is an aryl group. M is the same or different at each occurrence and is a conjugated moiety. T 1 and T 2 are independently the same or different at each occurrence and are conjugated moieties which are connected in a non-planar configuration; a and e are the same or different at each occurrence and are an integer from 1 to 6; b, c, and d are mole fractions such that b+c+d=1.0, with the proviso that c is not zero, and at least one of b and d is not zero, and when b is zero, M has at least two triarylamine units; and n is an integer greater than 1.

Подробнее
19-04-2012 дата публикации

Ionic liquid solvents of perhalide type for metals and metal compounds

Номер: US20120090430A1
Принадлежит: Individual

The present invention relates to a process for dissolving metals in perhalide containing ionic liquids, and to the extraction of metals from mineral ores; the remediation of materials contaminated with heavy, toxic or radioactive metals; and to the removal of heavy and toxic metals from hydrocarbon streams.

Подробнее
03-05-2012 дата публикации

Nitrogen-Containing Ligands And Their Use In Atomic Layer Deposition Methods

Номер: US20120108062A1
Принадлежит: Applied Materials Inc

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.

Подробнее
24-05-2012 дата публикации

Materials for organic electroluminescent devices

Номер: US20120126179A1
Принадлежит: Merck Patent GmBH

The present invention relates to 4,4′-substituted spirobifluorenes which are suitable, owing to excellent properties, as functional materials in organic electroluminescent devices. In addition, the present invention relates to a process for the preparation of 4,4′-substituted spirobifluorenes and to the use of these compounds in organic electroluminescent devices.

Подробнее
07-06-2012 дата публикации

Compositions and methods relating to proliferative diseases

Номер: US20120141578A1
Принадлежит: PENN STATE RESEARCH FOUNDATION

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.

Подробнее
07-06-2012 дата публикации

Process For The Synthesis Of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicycle[3.1.0]Hexane

Номер: US20120142940A1
Принадлежит: Euthymics Bioscience Inc, Merck and Co Inc

The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.

Подробнее
05-07-2012 дата публикации

Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives

Номер: US20120172426A1
Принадлежит: Reviva Pharmaceuticals Inc

The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Подробнее
09-08-2012 дата публикации

Monoamine derivative and organic electroluminescent element using same

Номер: US20120199820A1
Принадлежит: Idemitsu Kosan Co Ltd

An organic electroluminescence device includes: an anode; a cathode being opposed to the anode; and an emitting layer being provided between the anode and the cathode. The emitting layer includes a host material and a phosphorescent dopant material. The host material includes a monoamine derivative represented by a formula-(1A) below. In the formula (1A), each of Ar 1 , Ar 2 and Ar 4 is a substituted or unsubstituted aryl group or heteroaryl group, Ar 3 is a substituted or unsubstituted arylene group or heteroarylene group, n is an integer of 0 to 5, Ar 3 may be mutually the same or different when n is 2 or more, and at least one of Ar 1 , Ar 2 , Ar 3 , and Ar 4 is a group derived from a fused aromatic hydrocarbon skeleton having 3 or more rings.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
23-08-2012 дата публикации

High Stability Diionic Liquid Salts

Номер: US20120215005A1
Принадлежит: Sigma Aldrich Co LLC

The present invention relates to diionic liquid salts of dicationic or dianionic molecules, as well as solvents comprising diionic liquids and the use of diionic liquids as the stationary phase in a gas chromatographic column.

Подробнее
13-09-2012 дата публикации

Aromatic amine derivative and organic electroluminescent device using same

Номер: US20120228594A1
Принадлежит: Idemitsu Kosan Co Ltd

Disclosed is an organic electroluminescence device in which an organic thin film which is composed of one or more layers including at least a light-emitting layer is interposed between a cathode and an anode. Since at least one layer of the organic thin film contains a novel aromatic amine derivative, which has an asymmetric structure wherein two different amine units are bonded through a linking group, by itself or as a component of a mixture, molecules are hardly crystallized, thereby improving the production yield of the organic electroluminescence device. This organic electroluminescence device has a long life.

Подробнее
20-09-2012 дата публикации

Chrysenes for deep blue luminescent applications

Номер: US20120235562A1
Принадлежит: EI Du Pont de Nemours and Co

This disclosure relates to chrysene compounds with deep blue emission that are useful in electroluminescent applications. It also relates to electronic devices in which the active layer includes such a chrysene compound.

Подробнее
18-10-2012 дата публикации

Agents for enhanced charge transport across microbial membranes

Номер: US20120264649A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The invention provides molecules useful for enhancing charge transport across membranes, such as electron transport across membranes, and methods of using such molecules, for example in improving the performance of a microbial fuel cell or in staining microbes for observation. The amphiphilic molecule comprises a conjugated core with hydrophilic groups on either end. The amphiphilic molecule inserts into the membrane of a microbe and facilitates charge transfer across the membrane of the microbe.

Подробнее
18-10-2012 дата публикации

Salt forms of [R-(R*,R*)]-2-(4-flurorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Номер: US20120264934A1
Принадлежит: PFIZER INC

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Подробнее
18-10-2012 дата публикации

Biological Buffers with Wide Buffering Ranges

Номер: US20120264945A1
Автор: Thomas Daly
Принадлежит: Thomas Daly

Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.

Подробнее
22-11-2012 дата публикации

Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds

Номер: US20120295832A1
Принадлежит: Arrowhead Research Corp

The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.

Подробнее
06-12-2012 дата публикации

Palladium precursor composition

Номер: US20120308719A1
Автор: Ping Liu, Yiliang Wu
Принадлежит: Xerox Corp

A palladium precursor composition contains a palladium salt and an organoamine. The composition permits the use of solution processing methods to form palladium layers.

Подробнее
13-12-2012 дата публикации

Novel organic compound and organic light-emitting device

Номер: US20120313085A1
Принадлежит: Canon Inc

A novel organic compound suitable for blue light emission and an organic light-emitting device containing the novel organic compound are provided. An organic compound represented by the following general formula (1) wherein R 1 to R 18 independently denote a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group.

Подробнее
07-03-2013 дата публикации

Inhibiting neurotransmitter reuptake

Номер: US20130059864A1

This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.

Подробнее
21-03-2013 дата публикации

TRIPHENYLAMINE DERIVATIVES

Номер: US20130071780A1
Принадлежит: HODOGAYA CHEMICAL CO., LTD.

[Problems] To provide a novel compound useful as an electric charge transporting agent having a high carrier mobility, and making it possible not only to stably form a photosensitive layer without precipitating crystals or developing pinholes when the photosensitive layer is being formed but also to prepare an organic photosensitive material for electrophotography featuring a high sensitivity and a low residual potential. 9. A charge transporting agent comprising the triphenylamine derivative of .10. An organic photosensitive material for electrophotography having an organic photosensitive layer formed on an electrically conducting substrate claim 1 , said organic photosensitive layer containing the triphenylamine derivative of as a charge transporting agent.11. The organic photosensitive material for electrophotography according to claim 10 , wherein said organic photosensitive layer is a lamination type photosensitive layer which comprises a charge generating layer in which a charge generating agent is dispersed in a resin binder claim 10 , and a charge transporting layer in which the charge transporting agent is dispersed in a resin binder.12. The organic photosensitive material for electrophotography according to claim 10 , wherein said organic photosensitive layer is a single-layer type photosensitive layer in which the charge generating agent and the charge transporting agent are dispersed in a resin binder. This invention relates to triphenylamine derivatives having a high carrier mobility, are useful as an electric charge transporting agent which are used for a photosensitive material for electrophotography.Amorphous silicon, amorphous selenium, cadmium sulfide, zinc oxide and the like have heretofore been known as inorganic photoconductive materials. Inorganic photosensitive materials formed by using such photoconductive materials have been widely used in the field of electrophotography. However, selenium and cadmium sulfide are toxic substances and must be ...

Подробнее
21-03-2013 дата публикации

DRUGS, DERIVATIVES AND ANALOGS CONTAINING ADAMANTANE STRUCTURES OF NEW INDICATION APPLICATIONS OF ANTI-TUMOR

Номер: US20130072553A1
Автор: XU LIFENG
Принадлежит:

This invention relates to the drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor. The invention also relates to above compounds to treat tumors and other diseases with FIG. . These drugs, derivatives and analogs are generated by the modification of the parent or fragment structures and formation of pharmaceutically acceptable salts, complex salts or prodrug. The drugs, derivatives and analogs as described are administered alone or together with at least one known anti-tumor and immune chemotherapeutic agent including treatment of viral, bacterial and fungal diseases, neurological diseases, endocrine system diseases, and immune system diseases. 2. The drugs claim 1 , derivatives and analogs according to claim 1 , wherein:compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6, derivatives and analogs are generated by the modification of the parent or fragment structures.3. The drugs claim 2 , derivatives and analogs according to claim 2 , wherein: the derivatives and analogs prepared by direct synthesis or structural modification of the drugs as described compound 1 claim 2 , compound 2 claim 2 , compound 3 claim 2 , compound 4 claim 2 , compound 5 and compound 6 are relevance to the drugs as described compound 1 claim 2 , compound 2 claim 2 , compound 3 claim 2 , compound 4 claim 2 , compound 5 and compound 6 in chemical structures and pharmaceutical activities.4. The drugs claim 3 , derivatives and analogs according to claim 3 , wherein:The drugs, derivatives and analogs are selected from the exemplified examples or pharmaceutically acceptable salts formed by organic acid, inorganic acid, organic base, inorganic base, prodrug or complex salts.5. The drugs claim 3 , derivatives and analogs according to claim 3 , claim 3 , and wherein:This invention relates to the drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor including: the ...

Подробнее
28-03-2013 дата публикации

NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

Номер: US20130076604A1
Принадлежит: CANON KABUSHIKI KAISHA

Provided are a novel organic compound appropriate for emission of green light and an organic light-emitting device including the organic compound. Provided is a substituted or unsubstituted indeno[1,2,3-cd]naphtho[2,3-k]fluoranthene appropriate for emission of green light. The substituents of the indeno[1,2,3-cd]naphtho[2,3-k]fluoranthene are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group. 2. The organic compound according to claim 1 , wherein Rto Rare each independently selected from a hydrogen atom and a substituted or unsubstituted aryl group.4. An organic light-emitting device comprising:an anode;a cathode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an organic compound layer disposed between the anode and the cathode, the organic compound layer containing the organic compound according to .'}5. An organic light-emitting device comprising:an anode;a cathode; and{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'an organic compound layer disposed between the anode and the cathode, the organic compound layer containing the organic compound according to .'}6. The organic light-emitting device according to claim 4 , wherein the organic compound layer is a light-emitting layer.7. The organic light-emitting device according to claim 6 , wherein the organic light-emitting device emits green light.8. A display apparatus having a plurality of pixels claim 4 , each including the organic light-emitting device according to and a switching device connected to the organic light-emitting device.9. An image input apparatus comprising:an image input unit configured to input an image; and{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'a display unit configured to display the image, the display unit having a plurality of pixels, each ...

Подробнее
28-03-2013 дата публикации

Kinase protein binding inhibitors

Номер: US20130079297A1

The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.

Подробнее
28-03-2013 дата публикации

FUNGICIDE N-CYCLOALKYL-N-BICYCLIC-CARBOXAMIDE DERIVATIVES

Номер: US20130079524A1
Принадлежит:

The present invention relates N-cycloalkyl-N-bicyclic-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group; T represents O, S, N-R, N—OR, N—NRRor N—CN; Zrepresents a C-C-cycloalkyl group; X represents N or a CZand Z; Z; Land Lrepresent various substituents; their process of preparation; preparation intermediate compounds; their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. 116-. (canceled)18. The compound of wherein Zis a cyclopropyl.19. The compound of wherein Zis a non-substituted cyclopropyl.20. The compound of wherein Zis a hydrogen atom.21. The compound of wherein Lis CZZ.22. The compound of wherein Lis CZZand m is 1 or 2.23. The compound of wherein Zand each Zare independently selected from the group consisting of a hydrogen atom; a halogen atom; C-C-alkyl; C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; C-C-alkoxy; and C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different. The present invention relates to N-cycloalkyl-N-bicyclic-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.In international patent application WO-2007/014290 certain N-substituted-N-bicyclic-carboxamide or thiocarboxamide derivatives are generically embraced in a broad disclosure of numerous compounds of the following formula:wherein Wcan represent oxygen or sulphur; A can represent NH or CH; Rcan represent a phenyl or heterocyclic ring; G can represent a 5-membered heterocyclic ring, ...

Подробнее
04-04-2013 дата публикации

Curable Amine, Carboxylic Acid Flux Composition And Method Of Soldering

Номер: US20130082092A1
Принадлежит: Rohm and Haas Electronic Materials LLC

A curable flux composition is provided, comprising, as initial components: a resin component having at least two oxirane groups per molecule; a carboxylic acid; and, an amine fluxing agent represented by formula I: and, optionally, a curing agent. Also provided is a method of soldering an electrical contact using the curable flux composition.

Подробнее
11-04-2013 дата публикации

LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE

Номер: US20130090386A1
Принадлежит:

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CHC(=0)NH, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH—, —CHCH—, —CHCHCH—, and —CHCHCHCH—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH, —NH(C-Calkyl), —N(C-Calkyl)(C-Calkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A′)X-(A)-(B)—(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer. 1. A compound of Formula 1{'br': None, 'sub': 'X', '(A′)-(A)-(B)—(Z)-(L)-(D)\u2003\u20031'} (A) is heteroaryl or aryl;', {'sub': 2', '2, 'each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CHC(═O)NH, heteroaryl, cyano, sulfonyl, and sulfinyl;'}, 'X is 0, 1, 2, or 3;', '(B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B);', '(Z) is —NH—;', {'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, '(L) is chosen from a single bond, —CH—, —CHCH—, —CHCHCH—, and —CHCHCHCH—; and'}, {'sub': 2', '1', '6', '1', '6', '1', ...

Подробнее
25-04-2013 дата публикации

SELECTIVE SIGMA-1 RECEPTOR LIGANDS

Номер: US20130102571A1
Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

The invention provides compounds of the formulas described herein and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS. 3. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable diluent or carrier.5. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable diluent or carrier.7. The compound of wherein the compound exhibits selectivity for the σ-1 receptor over the σ-2 receptor and the σ-2 Ki:σ-1 Ki ratio is about 0.4 or less.8. The compound of wherein the compound exhibits selectivity for the σ-2 receptor over the σ-1 receptor and the σ-2 Ki:σ-1 Ki ratio is at least about 10.9. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable diluent or carrier.11. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable diluent or carrier.12. A method of modulating a sigma-1 receptor in a mammal comprising administering to the mammal an effective amount of a compound of claim 1 , so that the sigma-1 receptor is modulated claim 1 , wherein the modulating comprises agonism of the sigma-1 receptor or antagonism of the sigma-1 receptor.13. A method of modulating a sigma-1 receptor in a mammal comprising administering to the mammal an effective amount of a compound of claim 4 , so that the sigma-1 receptor is modulated claim 4 , wherein the modulating comprises agonism of the sigma-1 receptor or antagonism of the sigma-1 receptor.14. A method of modulating a ...

Подробнее
25-04-2013 дата публикации

ANTIMICROBIAL COMPOUNDS OF 1,4-NAPHTOQUINONE STRUCTURE

Номер: US20130102650A1
Принадлежит:

The present invention relates to a compound having formula (I) wherein: Ris chosen from the group consisting of: phenyl group, possibly substituted, —CH—CH—R′group, R′being chosen from the group consisting of: H, —OH, halogen, alkyl, aryl, CHO, —CN, —NO, —SR, —OR, —NRR, —CONRR, —COOR, and —NHCOR, Rand Rrepresenting independently from each other H, an alkyl group or an aryl group, R′being preferably in para position, and —CH—CO—R′ group, R′ representing an aryl or heteroaryl group, said aryl and heteroaryl groups being possibly substituted, Ris chosen from the group consisting of: —OH and halogen, and R, R, Rand Rare in particular H, for its use for the prevention and/or the treatment of bacterial infections. 3. The compound according to claim 1 , wherein Ris a substituted or unsubstituted phenyl group.4. The compound according to claim 1 , wherein Ris a phenyl group claim 1 , substituted by an aryl group.5. The compound according to claim 1 , wherein Ris chosen from the group consisting of: —CH—CH—R′group and —CH—CO—R′ group claim 1 , R′and R′ being as defined in .7. The compound according to claim 6 , wherein R′is a group in para position having formula —OR′ claim 6 , R′being H or an alkyl group comprising from 1 to 6 carbon atoms.8. The compound according to claim 6 , wherein Ris chosen from the groups having formula —CH—CO—R′ claim 6 , R′ being as defined in .9. The compound according to claim 8 , wherein R′ is a substituted and unsubstituted aryl group.10. The compound for the use according to claim 8 , wherein R′ is a substituted or unsubstituted phenyl group.12. The compound according to claim 11 , wherein R′is a group in para position chosen from the alkyl groups comprising from 1 to 6 carbon atoms claim 11 , and the groups having formula —OR′ claim 11 , R′being chosen from H and alkyl groups comprising from 1 to 6 carbon atoms.13. The compound according to claim 1 , wherein R′ is a substituted and unsubstituted heteroaryl group.15. (canceled)16. The ...

Подробнее
25-04-2013 дата публикации

NOVEL CURING AGENTS

Номер: US20130102756A1
Автор: Cawse John
Принадлежит: Hexcel Composites Limited

A curable resin comprising a compound having the structure (I): wherein each carbon 2, together with either its carbon 1 or carbon 3, arc members of a fused cycloaliphatic ring, and when carbon 1 is a member of the ring so is N, and wherein each of the aliphatic or aromatic ring-member carbons may either be members of further fused cycloaliphatic rings or be bonded to a group selected from H or linear or branched Cto Calkyl. 2. A curable resin according to claim 1 , wherein any carbons forming part of any further fused cycloaliphatic rings are also bonded to either an H or linear or branched Cto Calkyl.3. A curable resin according to claim 1 , wherein each of the aliphatic or aromatic ring-member carbons claim 1 , which are not members of a fused cycloaliphatic ring claim 1 , are bonded to an H or linear or branched Cto Calkyl.4. A curable resin according to claim 1 , wherein the compound has a molecular weight of no greater than 600.5. A curable resin according to claim 1 , wherein the fused cycloaliphatic rings comprise five or six carbons.8. A curable resin according to claim 1 , wherein carbon 2 is a member of two fused cycloaliphatic rings claim 1 , one with carbon 1 and the other with carbon 3.9. A curable resin according to claim 1 , having a melting point of from 80° C. to 200° C.10. A curable resin according to claim 1 , wherein the resin is an epoxy or urethane.11. A curable resin according to claim 1 , comprising a fibre reinforcement.12. A curable resin according to claim 11 , which is a prepreg claim 11 ,13. A cured resin made by exposing a curable resin according to to elevated temperature.14. A cured resin according to claim 13 , which has a glass transition temperature of greater than 100° C.15. A cured resin according to which forms part of a structural member of an aerospace structure. The present invention relates to novel resin curing agents, particularly for epoxy and urethane resins.Curable resin systems are widely known and have a wide range ...

Подробнее
25-04-2013 дата публикации

FUNGICIDE N-CYCLOALKYL-N-BICYCLIMETHYLENE-CARBOXAMIDE DERIVATIVES

Номер: US20130102790A1
Принадлежит:

The present invention relates to N-cycloalkyl-N-bicyclicmethylene-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group, T represents O or S, Zrepresents a C-C-cycloalkyl group, X represents N or a CZand Y, Y, Z, Z, Land Lrepresent various substituents. Their process of preparation, the preparation of intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions are also disclosed. 118-. (canceled)20. The compound of wherein Yis C-C-alkyl and Yis hydrogen.21. The compound of wherein Yis methyl.22. The compound of wherein Yand Yare both C-C-alkyl.23. The compound of wherein Yand Yare both methyl.24. The compound of wherein Zis hydrogen.25. The compound of wherein Lis CZZ.26. The compound of wherein Lis CZZand m is 1 or 2.27. The compound of wherein Zand each Zare independently selected from the group consisting of a hydrogen atom claim 19 , a halogen atom claim 19 , C-C-alkyl claim 19 , C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different claim 19 , C-C-alkoxy claim 19 , and C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different.28. The compound of wherein said compound is N-cyclopropyl-3-(difluoromethyl)-N-[1-(1-hydroxy-1 claim 19 ,2 claim 19 ,3 claim 19 ,4-tetrahydronaphthalen-1-yl)ethyl]-1-methyl-1H-pyrazole-4-carboxamide. The present invention relates to N-cycloalkyl-N-bicyclicmethylene-carboxamide or thiocarboxamide derivatives, their process of preparation, preparation of intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.In international patent application WO2007060164 ...

Подробнее
09-05-2013 дата публикации

Formulations, salts and polymorphs of transnorsertraline and uses thereof

Номер: US20130116332A1
Принадлежит: SUNOVION PHARMACEUTICALS INC

Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.

Подробнее
16-05-2013 дата публикации

Styryl-based compound, composition containing styryl-based compound, and organic light emitting diode including styryl-based compound

Номер: US20130119355A1
Принадлежит: Samsung Display Co Ltd

A styryl-based compound represented by Formula 1, a composition containing the styryl-based compound, and an organic light-emitting diode (OLED) including the styryl-based compound: The styryl-based compound may exhibit high heat resistance and thus an OLED including the same may have low driving voltage, high brightness, high efficiency, and long lifetime.

Подробнее
16-05-2013 дата публикации

Organic Electroluminescent Element, Material for Organic Electroluminescent Element, and Light Emitting Device, Display Device and Illumination Device Each Using the Element

Номер: US20130119359A1
Принадлежит: UDC IRELAND LIMITED

The disclosure relates to organic electroluminescent elements, materials for use in the elements, and devices using the elements, which include a compound represented by the following General Formula (1): 2. The organic electroluminescent element according to claim 1 , wherein in the General Formula (1) Rto Rare each selected from a hydrogen atom claim 1 , an alkyl group claim 1 , an aryl group claim 1 , a heteroaryl group claim 1 , —NYY claim 1 , —OY claim 1 , —SY claim 1 , a halogen atom claim 1 , and a silyl group claim 1 , and{'sup': 1', '4, 'wherein Yto Yeach independently represents an alkyl group, an aryl group or a heteroaryl group, and which may further have substituents.'}6. The organic electroluminescent element according to claim 4 , wherein in the General Formula (3) Land Leach independently represents an arylene group or a heteroarylene group.14. The organic electroluminescent element according to claim 1 , wherein the light emitting layer includes an anthracene-based host material.15. The organic electroluminescent element according to claim 1 , wherein the light emitting layer is formed by a vacuum deposition process.16. The organic electroluminescent element according to claim 1 , wherein the light emitting layer is formed by a wet process.17. A light emitting device comprising the organic electroluminescent element according to .18. A display device comprising the organic electroluminescent element according to .19. An illumination device comprising the organic electroluminescent element according to . This application claims the benefit of priority to Japanese Patent Application No. 2011-250945, filed Nov. 16, 2011, which is incorporated herein by reference in its entirety.The present invention relates to an organic electroluminescent element and a material for an organic electroluminescent element which can be used in the same. The present invention also relates to a light emitting device, a display device, or an illumination device each using ...

Подробнее
16-05-2013 дата публикации

Adhesive Compositions for Bonding Composites

Номер: US20130123513A1
Принадлежит: GEORGIA-PACIFIC CHEMICALS LLC

The present invention relates to a non-thermosetting composition made by reacting epichlorohydrin and a primary amine, to the use of that composition for making thermosetting (curable) adhesives suitable for bonding composites, to a method of preparing composites using the thermosetting (curable) adhesives, and to the related composites bonded with the thermosetting (curable) adhesives. 1. A non-thermosetting, reaction product of (a) epichlorohydrin and (b) an amine selected from the group consisting of ammonia, a primary amine and mixtures thereof, wherein the reaction product is produced by reacting the epichlorohydrin and the amine in a ratio of 0.40 to 0.92 moles of epichlorohydrin per atom equivalent of amine hydrogen and wherein the epi-amine reaction product is produced by reacting in a serial fashion separate portions of the epichlorohydrin and separate portions of the amine at a temperature of not greater than 60° C. This application is a divisional of co-pending U.S. patent application Ser. No. 12/718,391, filed on Mar. 5, 2010, which claims the benefit of U.S. Provisional Application No. 61/158,013 filed Mar. 6, 2009, each of which is hereby incorporated by reference in its entirety.The present invention is directed to a non-thermosetting composition made by reacting epichlorohydrin and an amine, to the use of that composition for making thermosetting (curable) adhesives, particularly adhesives suitable for bonding composites, to a method of preparing composites, particularly wood composites using the thermosetting (curable) adhesives, and to the related composites bonded with the cured thermosetting (curable) adhesives.A variety of composite materials are made by bonding into a unitary product a primary constituent, often a structural or reinforcement component, using a bonding agent or matrix material, such as an adhesive resin. Composites include engineered wood products (wood-adhesive composite products), insulation products and the like.Wood-adhesive ...

Подробнее
16-05-2013 дата публикации

METHOD FOR PRODUCING 2,5-DIAMINOTOLUENE

Номер: US20130123540A1
Автор: Aeby Johann, Goettel Otto
Принадлежит: ALFA PARF GROUP S.P.A.

The invention relates to a method for producing 2,5-diaminotoluene by catalytic hydrogenation in an aprotic-non-polar solvent or in a mixture made of two or more aprotic-nonpolar solvents with hydrogen in the presence of a catalyst or a mixture of two or more catalysts. The invention further relates to crystalline 2,5-diaminotoluene having characteristic crystal modification. As compared to conventional forms of administration common in industry, this is characterised in that it is largely insensitive to air oxidation. 1. A method for producing 2 ,5-diaminotoluene , comprising hydrogenating 2-methyl-4-nitroaniline in an aprotic nonpolar solvent or in a mixture made of two or more aprotic nonpolar solvents with hydrogen in the presence of a catalyst or a mixture made of two or more catalysts , thereby forming a solution containing 2 ,5-diaminotoluene and an aprotic nonpolar solvent or a mixture made of two or more aprotic nonpolar solvents.2. The method according to claim 1 , wherein the aprotic nonpolar solvent or the mixture made of two or more aprotic nonpolar solvents has a dielectric constant ∈in the range of 2.3 to 6.1.3. The method according to claim 1 , wherein the catalyst is a solid catalyst or the mixture made of two or more catalysts is a mixture containing at least one solid catalyst.4. The method according to claim 1 , wherein the catalyst is a palladium/activated carbon catalyst or the mixture made of two or more catalysts is a mixture containing at least one palladium/activated carbon catalyst.5. The method according to claim 1 , wherein the 2-methyl-4-nitroaniline is hydrogenated in a temperature range of 0° C. to 150° C.6. The method according to claim 1 , wherein the 2-methyl-4-nitroaniline is hydrogenated at a hydrogen overpressure in the range of 0 to 5 MPa.7. The method according to claim 1 , wherein at least one of the following steps is carried out after the hydrogenation:separating the catalyst or the mixture made of two or more catalysts ...

Подробнее
23-05-2013 дата публикации

Organic Electroluminescent Element, Compound for Use in the Element, and Light Emitting Device, Display Device, and Illumination Device Using the Element

Номер: US20130126835A1
Принадлежит: UDC IRELAND LIMITED

The disclosure relates to organic electroluminescent elements, compounds for use in the elements, and devices using the elements, which include a compound represented by the following General Formula (1): 5. The organic electroluminescent element according to claim 2 , wherein in the General Formula (2) Land Leach independently represents an arylene group or a heteroarylene group.6. The organic electroluminescent element according to claim 5 , wherein the substituent included in the arylene group or the heteroarylene group each independently represented by Land Lis only a substituent with a Hammett substituent constant σvalue of less than 0.1.8. The organic electroluminescent element according to claim 1 , wherein in the General Formula (1) Rto Rand Rto Reach independently represents a hydrogen atom claim 1 , which may be a deuterium atom claim 1 , an alkyl group claim 1 , an aryl group claim 1 , a heteroaryl group claim 1 , a silyl group claim 1 , an alkoxy group claim 1 , an alkylthio group claim 1 , an aryloxy group claim 1 , an arylthio group claim 1 , a halogen atom or a cyano group claim 1 , and which may have further substituents.9. The organic electroluminescent element according to claim 1 , wherein the organic electroluminescent element comprises a light emitting layer including an anthracene-based host material.10. The organic electroluminescent element according to claim 1 , wherein the organic electroluminescent element comprises a light emitting layer formed by a vacuum deposition process.11. The organic electroluminescent element according to claim 1 , wherein the organic electroluminescent element comprises a light emitting layer formed by a wet process.12. A light emitting device comprising the organic electroluminescent element according to .13. A display device comprising the organic electroluminescent element according to .14. An illumination device comprising the organic electroluminescent element according to .16. The compound according to ...

Подробнее
23-05-2013 дата публикации

CATIONIC LIPID

Номер: US20130129811A1
Принадлежит:

The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) 2. The cationic lipid according to claim 1 , wherein Xand Xare combined together to form a single bond or alkylene.3. The cationic lipid according to claim 1 , wherein Lis a single bond claim 1 , Ris a hydrogen atom claim 1 , methyl claim 1 , pyrrolidin-3-yl claim 1 , piperidin-3-yl claim 1 , piperidin-4-yl claim 1 , or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s) claim 1 , which is(are) claim 1 , the same or different claim 1 , amino claim 1 , monoalkylamino claim 1 , dialkylamino claim 1 , trialkylammonio claim 1 , hydroxy claim 1 , alkoxy claim 1 , carbamoyl claim 1 , monoalkylcarbamoyl claim 1 , dialkylcarbamoyl claim 1 , pyrrolidinyl claim 1 , piperidyl or morpholinyl claim 1 , and Land Lare —O—.4. The cationic lipid according to claim 1 , wherein Lis —CO— or —CO—O— claim 1 , Ris pyrrolidin-3-yl claim 1 , piperidin-3-yl claim 1 , piperidin-4-yl claim 1 , or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s) claim 1 , which is(are) claim 1 , the same or different claim 1 , amino claim 1 , monoalkylamino claim 1 , dialkylamino claim 1 , trialkylammonio claim 1 , hydroxy claim 1 , alkoxy claim 1 , carbamoyl claim 1 , monoalkylcarbamoyl claim 1 , dialkylcarbamoyl claim 1 , pyrrolidinyl claim 1 , piperidyl or morpholinyl claim 1 , wherein at least one of the substituents is amino claim 1 , monoalkylamino claim 1 , dialkylamino claim 1 , trialkylammonio claim 1 , pyrrolidinyl claim 1 , piperidyl or morpholinyl claim 1 , and Land Lare identically —CO—O— or —O—CO—.5. The cationic lipid according to any one of to claim 1 , wherein Xis absent claim 1 , or is methyl.64. The cationic lipid according to any one of to claims 1 , wherein Land Lare —O— or —O—CO— claims 1 , and Rand Rare (Z)-hexadec-6-enyl or (Z)-hexadec ...

Подробнее
30-05-2013 дата публикации

Ionomers and Methods of Making Same and Uses Thereof

Номер: US20130137011A1
Принадлежит: CORNELL UNIVERSITY

Ionomers comprising ionic groups such as, for example, tetraalkylammonium groups and methods of making such ionomers. For example, the ionomers can be produced by ring opening metathesis polymerization of alkene-containing monomers with tetraalkylammonium groups and, optionally, alkene-containing monomers without tetraalkylammonium groups. The ionomers can be used in applications such as, for example, fuel cell applications. 1) An ionomer comprising ionic strained olefin monomer (ISOM) units and optionally random or sequentially placed strained olefin monomer (SOM) units , having the following structure:{'br': None, 'sub': X', '1-X, '\ue8a0ISOM\ue8a0\ue8a0SOM\ue8a0'}wherein the ISOM and SOM units are connected by carbon-carbon single bonds and/or carbon-carbon double bonds,wherein the ISOM unit has a non-aromatic hydrocarbon backbone and comprises one or more tetraalkylammonium groups connected to the backbone by an aliphatic polyatomic linkage, and any carbon atoms in the beta position relative to an ammonium nitrogen do not bear hydrogen substituents,wherein the SOM unit is a non-aromatic hydrocarbon unit, andwherein x is from 0.05 to 1.0.2) The ionomer of claim 1 , wherein the number average molecular weight of the ionomer claim 1 , Mn claim 1 , is from 5 claim 1 ,000 to 1 claim 1 ,000 claim 1 ,000 g/mol and/or the weight average molecular weight of the ionomer claim 1 , Mw claim 1 , is from 5 claim 1 ,000 to 2 claim 1 ,000 claim 1 ,000 g/mol.3) The ionomer of claim 1 , wherein the end groups of the ionomer are independently selected from ═CH claim 1 , ═CHR (where R is CHW where W is H claim 1 , alkyl claim 1 , halide claim 1 , hydroxide or acetate) claim 1 , ═CHPh claim 1 , —CH claim 1 , —CHR (where R is CHW where W is H claim 1 , alkyl claim 1 , halide claim 1 , hydroxide or acetate claim 1 ,) and —CHPh.6) The ionomer of claim 1 , wherein at least one first ISOM or SOM unit is connected by a polyatomic linking group (PAL) comprising a Cto Cgroup claim 1 , ...

Подробнее
30-05-2013 дата публикации

Method of producing gallium phthalocyanine crystal and method of producing electrophotographic photosensitive member using the method of producing gallium phthalocyanine crystal

Номер: US20130137032A1
Принадлежит: Canon Inc

Provided is a method of producing an electrophotographic photosensitive member having improved sensitivity and capable of outputting an image having less image defects due to a ghost phenomenon not only under a normal-temperature, normal-humidity environment but also under a low-temperature, low-humidity environment as a particularly severe condition. The method of producing a gallium phthalocyanine crystal includes subjecting a gallium phthalocyanine and a specific amine compound, which are added to a solvent, to a milling treatment to perform crystal transformation of the gallium phthalocyanine. In addition, the gallium phthalocyanine crystal is used in the photosensitive layer of the electrophotographic photosensitive member.

Подробнее
30-05-2013 дата публикации

Organic light-emitting material, organic light-emitting element using the same and method of forming the same

Номер: US20130137206A1
Принадлежит: National Chiao Tung University NCTU

The present invention provides compound of formula (I) wherein each substituent is defined in the specification. The compound may be used, in combination with other organic light-emitting materials, in a light-emitting layer of an organic light-emitting element. The present invention also provides an organic light-emitting element including a first electrode, a second electrode and at least three layers of organic material layers disposed between the first electrode and the second electrode, wherein the layer used as a light-emitting layer contains a compound of formula (I). Further, an all-solution process, which is used for fabricating the organic light-emitting element of the present invention, has the advantages such as avoiding miscibility among the layers to fabricate an element with a large surface area and lower production cost.

Подробнее
30-05-2013 дата публикации

Cyclopropene amine compounds

Номер: US20130137575A1
Автор: Edward C. Sisler
Принадлежит: North Carolina State University

Methods of applying cyclopropene amine derivatives and compositions thereof to inhibit ethylene receptors in plants and plant material are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of at least one cyclopropene amine compound or composition thereof. Cyclopropene amine compounds, enantiomers, stereoisomers or salts thereof are also provided.

Подробнее
30-05-2013 дата публикации

Novel method of preparing secondary amine compound using microflow reactor

Номер: US20130137900A1

Disclosed is a novel method of preparing a secondary amine compound using a microflow reactor. According to the method, a primary amine compound and a halide compound are allowed to react with each other in the microflow reactor, such that the production of a tertiary amine compound or an ammonium salt is minimized, whereby the secondary amine compound is efficiently prepared.

Подробнее
11-07-2013 дата публикации

INDENOPERYLENE COMPOUND, MATERIAL FOR ORGANIC THIN-FILM PHOTOVOTAIC CELL CONTAINING INDENOPERYLENE DERIVATIVE AND ORGANIC THIN FILM PHOTOVOTAIC CELL USING SAME

Номер: US20130174910A1
Принадлежит: IDEMITSU KOSAN CO., LTD.

An indenoperylene derivative represented by a formula (A-1), wherein in the formula (A-1), at least one of Rto Ris an amino group represented by the formula (A-2). In the formula (A-2), Rand Rare a substituted or unsubstituted aryl group having 6 to 40 ring carbon atoms or a substituted or unsubstituted alkyl group having 1 to 40 carbon atoms. 4. A material for an organic thin film solar cell comprising the indenoperylene derivative according to .5. An organic thin film solar cell comprising the indenoperylene derivative according to .6. An organic thin film solar cell comprising at least a p layer claim 1 , wherein the p layer comprises the indenoperylene derivative according to .7. An organic thin film solar cell comprising at least a p layer and an n layer claim 1 , wherein the n layer comprise a fullerene derivative and the p layer comprises the indenoperylene derivative according to .10. An organic thin film solar cell comprising the material for an organic thin film solar cell according to .11. An organic thin film solar cell having at least a p layer claim 8 , wherein the p layer comprises the material for an organic thin film solar cell according to .12. An organic thin film solar cell comprising at least a p layer and an n layer claim 8 , wherein the n layer comprises a fullerene derivative and the p layer comprises the material for an organic thin film solar cell according to . The invention relates to a novel indenoperylene derivative, a material for an organic thin film solar cell comprising the same, and an organic thin film solar cell using the same. The invention relates to a material for an organic thin film solar cell comprising an indenoperylene derivative and an organic thin film solar cell using the same.An organic thin film solar cell is a device which outputs electric power through input of light. In this regard, it is a device which shows a response opposite to an organic electroluminescence (EL) device which outputs light through input of ...

Подробнее
11-07-2013 дата публикации

METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS

Номер: US20130178520A1
Принадлежит: Duke University

Described herein are methods of treating Parkinson's disease using arylcyclopropylamine compounds. 2. The method of claim 1 , wherein R claim 1 , R claim 1 , Rand Rare hydrogen.3. The method of claim 1 , wherein Ris selected from Chaloalkyl claim 1 , halo claim 1 , Calkoxy claim 1 , and Caryloxy.4. The method of claim 1 , wherein Rand Rare taken together with the carbon atoms to which they are attached to form a Cheterocyclyl ring.5. The method of claim 4 , wherein Rand Rare taken together to form a five-membered heterocyclyl ring.6. The method of claim 1 , wherein Ris hydrogen.818.-. (canceled)20. The method of claim 19 , wherein A is a heterocyclyl ring.21. The method of claim 19 , wherein A is a bicyclic heterocyclyl ring.27. The method of claim 26 , wherein Xand Xare O.28. The method of claim 26 , wherein n is 1.2939.-. (canceled) This application claims priority to U.S. Provisional Patent Application No. 61/579,872, filed on Dec. 23, 2011, the entire contents of which are hereby incorporated by reference.This invention was made with United States Government support awarded by National Institutes of Health, Grant No. GM65539. The U.S. Government has certain rights in this invention.Although there is no known cure for Parkinson's disease (PD), one of the two most common neurodegenerative diseases of aging, dopamine (DA) replacement therapy by administration of the DA biosynthetic precursor levodopa (L-DOPA or LD) has been employed for over 40 years as the gold standard for treatment of PD-associated symptoms. However, the efficacy of this treatment may wane with time, and the drug may have a number of long-term side-effects including L-DOPA-induced dyskinesias (LIDs), fluctuations in motor performance, and hallucinations. Often these effects can become dose limiting at a time when patients are in need of more medication and not less. DA agonists, as well as several other classes of drugs directly or indirectly affecting DA function (monoamine oxidase (MAO) ...

Подробнее
11-07-2013 дата публикации

NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY

Номер: US20130178541A1
Принадлежит:

The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA. 2. A cationic lipid of Formula A according to claim 1 ,wherein:{'sup': 1', '2, 'Rand Rare each methyl;'}{'sup': '3', 'Ris H;'}n is 0;{'sub': 1', '4', '24', '4', '24, 'Lis selected from C-Calkyl and C-Calkenyl; and'}{'sub': 2', '3', '9', '3', '9, 'Lis selected from C-Calkyl and C-Calkenyl;'}or any pharmaceutically acceptable salt or stereoisomer thereof.3. A cationic lipid of Formula A according to claim 1 ,wherein:{'sup': 1', '2, 'Rand Rare each methyl;'}{'sup': '3', 'Ris H;'}n is 2;{'sub': 1', '4', '24', '4', '24, 'Lis selected from C-Calkyl and C-Calkenyl; and'}{'sub': 2', '3', '9', '3', '9, 'Lis selected from C-Calkyl and C-Calkenyl;'}or any pharmaceutically acceptable salt or stereoisomer thereof.4. The cationic lipid according to which is selected from:(20Z,23Z)—N,N-dimethylnonacosa-20,23-dien-10-amine (Compound 1);(17Z,20Z)—N,N-dimethylhexacosa-17,20-dien-9-amine (Compound 2);(16Z,19Z)—N,N-dimethylpentacosa-16,19-dien-8-amine (Compound 3);(13Z,16Z)—N,N-dimethyldocosa-13,16-dien-5-amine (Compound 4);(12Z,15Z)—N,N-dimethylhenicosa-12,15-dien-4-amine (Compound 5);(14Z,17Z)—N,N-dimethyltricosa-14,17-dien-6-amine (Compound 6);(15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-7-amine (Compound 7);(18Z,21Z)—N,N-dimethylheptacosa-18,21-dien-10-amine (Compound 8);(15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-5-amine (Compound 9);(14Z,17Z)—N,N-dimethyltricosa-14,17-dien-4-amine (Compound 10);(19Z,22Z)—N,N-dimethyloctacosa-19,22 ...

Подробнее
11-07-2013 дата публикации

MONOCATIONIC POLYHYDROXYL COMPOUNDS

Номер: US20130178542A1
Принадлежит: Dow Global Technologies LLC

Described are novel monocationic polyhydroxyl compounds and their uses in personal care compositions. 2. The compound of claim 1 , wherein Rand Rare each H.3. The compound of claim 1 , wherein Rand Rare each H.4. The compound of claim 1 , wherein Rand Rare each —CH.5. The compound of claim 1 , wherein Rand Rare each —CHCH(OH)CHOH.6. The compound of claim 1 , wherein Rand Rare each —CHCHOH.7. The compound of claim 1 , wherein Ris —(CH)CHand Ris —CHCHOH.8. The compound of claim 1 , wherein Ris —CHOH.9. The compound of claim 1 , wherein Ris —CHCH.10. The compound of claim 1 , wherein Rand Rcooperate to form a cyclohexyl group.12. A method for providing humectancy in a personal care composition claim 1 , comprising including the compound of into the personal care composition.13. A hair care composition containing the compound of .14. A skin care composition containing the compound of . The present invention relates to novel monocationic polyhydroxyl compounds and their uses in personal care compositions.Polyhydroxyl compounds, or polyols, have a number of uses, from raw materials used in the manufacture of urethane foams to humectants for personal care products like shaving foams, lotions, and shampoos.Quaternary ammonium compounds are also useful in a number of applications, such as for disinfectants, surfactants, fabric softeners, and conditioners in shampoos.Despite the number of available conventional compounds, there is a strong need for novel compounds with properties to differentiate performance or offer synergistic effects in areas of interest, particularly in personal care compositions.In one embodiment, the present invention provides compounds, including salts, of the Formula (I):wherein:The term “optionally substituted” as used herein means that the groups in question are either unsubstituted or substituted with one or more groups, radicals or moieties, selected from halogen, hydroxy, amino or carboxy. When the groups in question are substituted with more ...

Подробнее
11-07-2013 дата публикации

Processes for preparing 3-benzazepines

Номер: US20130178620A1
Принадлежит: Arena Pharmaceuticals Inc

The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.

Подробнее
18-07-2013 дата публикации

ANTI-MICROBIAL AND ANTI-STATIC SURFACE TREATMENT AGENT WITH QUATERNARY AMMONIUM SALT AS ACTIVE INGREDIENT AND METHOD FOR PREVENTING STATIC ELECTRICITY IN POLYMER FIBERS USING SAME

Номер: US20130183456A1
Автор: KIM Seong Cheol

Provided are an anti-static and anti-microbial surface treatment agent including a quaternary ammonium salt compound as an active ingredient and a method of preventing a polymer fiber from developing static electricity by using the surface treatment agent. The quaternary ammonium salt compound has excellent anti-static and anti-microbial effects for the prevention or improvement of static electricity in a polymer fiber. Accordingly, the quaternary ammonium salt compound is suitable for use as a fabric softener, or an anti-static agent, and also, provides anti-microbial effects to a polymer fiber. 2. A method of preventing static electricity in a polymer fiber claim 1 , comprising treating the polymer fiber with a surface treatment agent of .3. The method of claim 1 , wherein the method comprises: dipping the polymer fiber in a solvent; and treating the polymer fiber with the surface treatment agent of and a reaction catalyst.4. The method of claim 3 , wherein the reaction catalyst is treated at room temperature.5. The method of claim 3 , further comprising claim 3 , prior to the treating the polymer fiber with the surface treatment agent of claim 3 , forming a radical of the polymer fiber by using at least one treatment selected from (i) a treatment with a reaction catalyst claim 3 , (ii) irradiation of gamma ray claim 3 , (iii) irradiation of E-beam claim 3 , (iv) irradiation of ion-beam claim 3 , (v) irradiation of deep ultra violet (UV) light claim 3 , and (vi) a plasma treatment.6. The method of claim 5 , comprisingforming a radical of the polymer fiber by using at least one treatment selected from (i) a treatment with a reaction catalyst, (ii) irradiation of gamma ray, (iii) irradiation of E-beam, (iv) irradiation of ion-beam, (v) irradiation of deep ultra violet (UV) light, and (vi) a plasma treatment; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'adding the surface treatment agent of to the radical of the polymer fiber to form a covalent bond with a ...

Подробнее
18-07-2013 дата публикации

N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES

Номер: US20130184279A1
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY

Compounds of formula Ia and Ib 2. The compound of claim 1 , wherein A is:{'sub': 1', '6', '40', '46', '1', '6', '29', '30', '40', '40', '40', '40', '40', '40', '1', '6, "(a) phenyl, which is substituted with one or more substituents selected from the group consisting of: 1) halo, 2) (C-C)-alkyl, which may be optionally substituted with one or more R's, 3) —OR, 4) (C-C)-alkylthio, 5) cyano, 6) nitro, 7) —NRR, 8) aryl, which may be optionally substituted with one or more R's, 9) arylalkyl, which may be optionally substituted with one or more R's, 10) heteroaryl, which may be optionally substituted with one or more R's, 11) heteroarylalkyl, which may be optionally substituted with one or more R's, 12) heterocyclyl, which may be optionally substituted with one or more R's, 13) heterocyclylalkyl, which may be optionally substituted with one or more R's, 14) halo(C-C)alkyl,"}{'sub': 46', 'p', '46', '2', '46', '46, '15) —COR, 16) ═O, 17) —S(O)R, 18) —SONHR, 19) —COOR,'}{'sub': 46', '46', '46', '2', '6', '40', '2', '6', '40', '46', '46', '46', '46', '40, "20) —NHC(CN)NHR, 21) —CONRR, 22) (C-C)-alkynyl, which may be optionally substituted with one or more R's, 23) (C-C)-alkenyl, which may be optionally substituted with one or more R's, 24) —OCOR, 25) —OCOOR, or 26) —OCONRR; or any two adjacent substituents may join together to form a 4- to 8-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S and be optionally substituted with one or more R's;"}{'sub': 1', '6', '40', '46', '1', '6', '29', '30', '40', '40', '40', '40', '40', '40', '1', '6, "(b) heteroaryl, which is substituted with one or more substituents selected from the group consisting of: 1) halo, 2) (C-C)-alkyl, which may be optionally substituted with one or more R's, 3) —OR, 4) (C-C)-alkylthio, 5) cyano, 6) nitro, 7) —NRR, 8) aryl, which may be optionally substituted with one or more R's, 9) arylalkyl, which may be optionally substituted with one or more R's, 10) heteroaryl, which ...

Подробнее
25-07-2013 дата публикации

Small-Molecule-Targeted Protein Degradation

Номер: US20130190340A1
Принадлежит: Brandeis University

Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein. 1. A compound , comprising: a protein-binding moiety which binds a protein , a tag which promotes the degradation of said protein , and a covalent linker which connects the protein-binding moiety to the tag.2. (canceled)3. The compound of claim 1 , wherein the protein is selected from the group consisting of glutathione-S-transferase α1 (GST) claim 1 , dihydrofolate reductase (DHFR) claim 1 , botulinum toxin (BoNT) claim 1 , Bcr-Abl claim 1 , thioredoxin interacting protein (TXNIP) claim 1 , mutant forms of Ras that cause cancer claim 1 , and mutant forms of IMP dehydrogenase type 1 (IMPDH1) that cause retinitis pigmentosa.4. The compound of claim 1 , wherein the protein is a fusion protein comprising a first protein and a second protein; the protein-binding moiety binds the first protein; and the tag promotes the degradation of the second protein.5. The compound of claim 4 , wherein the first protein is GST claim 4 , DHFR claim 4 , SNAP claim 4 , CLIP claim 4 , or HALO.67-. (canceled)8. The compound of claim 1 , wherein the covalent linker comprises an alkylene.9. (canceled)10. The compound of claim 1 , wherein the covalent linker is —N(H)[CH]N(H)— claim 1 , —(OCHCH)O— claim 1 , or —(OCHCH)NH—; and n is 1-10 inclusive.1112-. (canceled)13. The compound of claim 1 , wherein the covalent linker comprises a triazolyl moiety.14. The compound of claim 1 , wherein the tag ...

Подробнее
25-07-2013 дата публикации

CALCIUM RECEPTOR-ACTIVE MOLECULES

Номер: US20130190407A1
Принадлежит: NPS PHARMACEUTICALS, INC.

The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies. 76. (canceled)78. The compound of or a pharmaceutically acceptable salt thereof claim 77 , wherein Yand Yare each independently a phenyl claim 77 , or 1- or 2-napthyl.79. The compound of or a pharmaceutically acceptable salt thereof claim 78 , wherein Yis independently a phenyl or 2-napthyl; and Yis independently a phenyl or 1-naphthyl.80. The compound of or a pharmaceutically acceptable salt thereof claim 79 , wherein Ris a methyl; and Ris a hydrogen.82. The compound of or a pharmaceutically acceptable salt thereof wherein the cycloaliphatic ring is selected from the group consisting of: cyclopropyl claim 77 , cyclobutyl claim 77 , cyclopentyl claim 77 , cyclopropylmethyl claim 77 , and cyclohexyl.838284. A pharmaceutical composition comprising a pharmaceutically acceptable carrier claim 77 , and a compound of any one of - or or a pharmaceutically acceptable salt thereof.84. The compound of or a pharmaceutically acceptable salt thereof claim 77 , wherein Alkyl is a C-Chydrocarbon having spor sphybridization and further comprises linear or branched moieties claim 77 , or a combination ...

Подробнее
01-08-2013 дата публикации

CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS

Номер: US20130197013A1
Принадлежит:

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. 4. The compound of wherein (G) is a heterocyclyl.5. (canceled)6. The compound of wherein (G) is phenyl.78-. (canceled)9. The compound of wherein E is —X═X— claim 1 , and X claim 1 , X claim 1 , Xand Xare independently C(R2) or N.10. The compound of wherein E is —X═X— claim 1 , and X claim 1 , X claim 1 , Xand Xare independently C(R2).1112-. (canceled)13. The compound of wherein E is —S— claim 1 , and Xand Xare independently C(R2) or N.1420-. (canceled)21. The compound of wherein each (R1) is independently chosen from alkyl claim 1 , aryl claim 1 , amino claim 1 , amido claim 1 , nitro claim 1 , halo claim 1 , haloalkyl claim 1 , haloalkoxy claim 1 , cyano claim 1 , heterocycle claim 1 , sulfonyl claim 1 , sulfonamide claim 1 , hydroxyl claim 1 , or alkoxy.22. The compound of wherein each (R1) is independently chosen from —CF claim 1 , —F claim 1 , —Cl claim 1 , —CN claim 1 , —CH claim 1 , —OH claim 1 , —OCH claim 1 , —C(═O)NH claim 1 , —NH—CO—CH claim 1 , —NH—SO—CH claim 1 , —NH—SO—CH—CH claim 1 , —NH—SO—CH(CH)—CH claim 1 , —NH—SO—(CH) claim 1 , —NH—SO—(CH)—CN claim 1 , —NHSOCF claim 1 , or —S(═O)NHCH.2328-. (canceled)30. The compound of wherein E is —S— or —X═X—.3137-. (canceled)38. The compound of wherein (G) is an aryl or heterocyclyl.3941-. (canceled)42. The compound of wherein each (R1) is independently chosen from alkyl claim 29 , aryl claim 29 , amino claim 29 , amido claim 29 , nitro claim 29 , halo claim 29 , haloalkyl claim 29 , cyano claim 29 , heterocyclyl claim 29 , sulfonyl claim 29 , sulfonamide claim 29 , hydroxyl claim 29 , or alkoxy.4446-. (canceled)47. The compound of wherein (G) is an aryl or heterocyclyl.4850-. (canceled)51. The compound of wherein each (R1) is independently chosen from alkyl claim 43 , aryl ...

Подробнее
01-08-2013 дата публикации

SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES

Номер: US20130197095A1
Принадлежит: Grünenthal GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. 2. Compound according to claim 1 , wherein n=0 and X stands for —NR—.5. Compound according to claim 1 , wherein{'sub': 1-8', '1-8, 'Q stands for —C-aliphatic, -aryl, —C-aliphatic-aryl, -heteroaryl, —C(═O)-heteroaryl or —C(═NH)-heteroaryl;'}{'sub': 1', '3, 'Rstands for —CH;'}{'sub': 2', '3, 'Rstands for —H or —CH;'}{'sub': 'A', 'X stands for —O— or —NR—;'}{'sub': A', '1-8, 'Rstands for —H or —C-aliphatic;'}{'sub': B', '1-8', 'B, 'Rstands for —H or —C-alkyl; on condition that when X stands for —O— and at the same time n stands for 0, Rdoes not stand for —H;'}{'sub': C', '2', '3', '3, 'Rstands for —H, —F, —Cl, —Br, —I, —CN, —NO, —CF, —OH or —OCH; and'}n stands for 0, 1, 2, 3 or 4;wherein alkyl, aliphatic, aryl and heteroaryl are respectively unsubstituted or mono- or polysubstituted.6. Compound according to claim 5 , wherein{'sub': 1-8', '1-8, 'Q stands for —C-alkyl, -phenyl, —C-alkyl-phenyl, -indolyl, —C(═O)-indolyl or —C(═NH)-indolyl;'}{'sub': 1', '3, 'Rstands for —CH;'}{'sub': 2', '3, 'Rstands for —H or —CH;'}{'sub': 'A', 'X stands for —O— or —NR—;'}{'sub': A', '1-8, 'Rstands for —H or —C-alkyl;'}{'sub': B', '1-8', 'B, 'Rstands for —H or —C-alkyl; on condition that when X stands for —O— and at the same time n stands for 0, Rdoes not stand for —H;'}{'sub': C', '2', '3', '3, 'Rstands for —H, —F, —Cl, —Br, —I, —CN, —NO, —CF, —OH or —OCH; and'}n stands for 0, 1, 2, 3 or 4;wherein alkyl, aliphatic, aryl and heteroaryl are respectively unsubstituted or mono- or polysubstituted.9. A pharmaceutical composition comprising at least one compound according to claim 1 , said compound being in the form of a single stereoisomer or mixture thereof claim 1 , the free compound and/or a physiologically compatible salt thereof claim 1 , ...

Подробнее
01-08-2013 дата публикации

Method for producing bis(aminomethyl)cyclohexanes

Номер: US20130197269A1
Принадлежит: Mitsui Chemicals Inc

A method for producing bis(aminomethyl)cyclohexanes includes a nuclear hydrogenation step of producing hydrogenated phthalic acids or phthalic acid derivatives by nuclear hydrogenation of phthalic acids or phthalic acid derivatives of at least one selected from the group consisting of phthalic acids, phthalic acid esters, and phthalic acid amides; a cyanation step of treating the hydrogenated phthalic acids or phthalic acid derivatives obtained in the nuclear hydrogenation step with ammonia, thereby producing dicyanocyclohexanes; and an aminomethylation step of treating the dicyanocyclohexanes obtained in the cyanation step with hydrogen, thereby producing bis(aminomethyl)cyclohexanes. In the cyanation step, metal oxide is used as a catalyst, and the obtained dicyanocyclohexanes have a metal content of 3000 ppm or less.

Подробнее
08-08-2013 дата публикации

TRIPHENYLENE-BASED MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES

Номер: US20130200359A1
Принадлежит: Merck Patent GmBH

The present invention relates to compounds of the formula (1) and (2) which are suitable for use in electronic devices, in particular organic electroluminescent devices. 115-. (canceled)19. The compound according claim 16 , wherein claim 16 , in compounds of the formula (1) where n=0 or in compounds of the formula (4) or formula (4a) claim 16 , X is selected from the group consisting of C(R) claim 16 , Si(R)and N(R) and Rstands claim 16 , identically or differently on each occurrence claim 16 , for an aromatic or heteroaromatic ring system having 5 to 40 aromatic ring atoms claim 16 , which may in each case also be substituted by one or more radicals Rand where two radicals Rmay also form an aromatic ring system with one another;and in that, in compounds of the formula (1) where X=formula (3) or in compounds of the formula (5) or formula (5a), the two triphenylene moieties which are bonded to A are in each case substituted identically and A stands for carbon or silicon;{'sup': 2', '2', '2', '2', '2', '2', '2', '2, 'sub': 2', '2', '2', '2, 'and in that, in compounds of the formula (1) where n=1 or in compounds of the formula (6) or formula (6a), the group X—Y—X is selected from the group consisting of C(R)—O—C(R), Si(R)—O—Si(R), O—BR—O, O—PR—O, O—P(═O)R—O and C(═O)—NR—C(═O);'}and in that, in compounds of the formula (2) or (7) or (7a), the two radicals R are identical.20. A process for the preparation of the compound according to which comprises reacting 1 claim 16 ,12-dilithiotriphenylene derivatives with electrophiles or by reaction of halogen- or amino-substituted triphenylene derivatives in a metal-catalyzed coupling reaction.21. An oligomer claim 16 , polymer or dendrimer containing one or more of the compounds according to claim 16 , where one or more bonds are present from the compound to the polymer claim 16 , oligomer or dendrimer.22. An electronic device which comprises the compound according to .23. An electronic device which comprises the oligomer claim ...

Подробнее
08-08-2013 дата публикации

AMINE COMPOUND, ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE

Номер: US20130202994A1
Принадлежит:

To provide an amine compound, represented by General Formula (I) below: 4. The electrophotographic photoconductor according to claim 3 , wherein the photoconductive layer includes a charge transport material.8. The electrophotographic photoconductor according to claim 4 , wherein the charge transport material is a polymeric charge transport material.11. The electrophotographic photoconductor according to claim 3 , wherein the electrophotographic photoconductor includes a protective layer on an outermost surface claim 3 , and the protective layer includes the amine compound represented by General Formula (I).12. The electrophotographic photoconductor according to claim 11 , wherein the protective layer includes a filler.13. The electrophotographic photoconductor according to claim 11 , wherein the protective layer includes a resin formed by curing a polymerizable monomer.15. The image forming apparatus according to claim 14 , wherein the exposure unit is any one of a laser diode and a light-emitting diode claim 14 , and the electrostatic latent image is digitally written on the electrophotographic photoconductor using the exposure unit. 1. Field of the InventionThe present invention relates to: an amine compound; an electrophotographic photoconductor including the amine compound; and an image forming method, an image forming apparatus and a process cartridge using the electrophotographic photoconductor.2. Description of the Related ArtIn recent years, development of an information-processing system device using an electrophotographic method is remarkable. In particular, a laser printer and a digital copier, which convert information to digital signals and carry out information recording with light, have improved significantly in terms of their print quality and reliability. Further, through combination with high-speed technology, they have been applied to a laser printer or a digital copier with which a full-color printing is possible. From such a background, to have ...

Подробнее
08-08-2013 дата публикации

Compounds for Prevention of Cell Injury

Номер: US20130203830A1
Принадлежит: SULFATEQ B.V.

The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation. 1. A compound capable of increasing or maintaining the H2S level in a cell for use in the prevention of cell injury and/or protection of a cell.2. The compound of claim 1 , wherein the increase or maintenance of the H2S level in the cell is mediated by endogenous H2S production in a cell for use in the prevention of cell injury and/or protection of a cell.3. The compound of claim 1 , wherein the compound is selected from the group consisting of serotonin claim 1 , baclofen claim 1 , dopamine claim 1 , propofol claim 1 , melatonin claim 1 , histamine claim 1 , D/L phenylserine claim 1 , trolox claim 1 , reduced trolox and/or a salt claim 1 , a derivate claim 1 , or a precursor thereof.4. The compound of claim 1 , wherein the endogenous H2S production is mediated by cystathionine beta synthase (CBS).5. The compound of claim 1 , wherein the compound is transferred into the cell via active transport.6. The compound of claim 1 , wherein the prevention of cell injury and/or the protection of a cell against injury is achieved in the treatment of subjects suffering from a disorder that mediates oxidative stress to cells.7. The compound of claim 1 , wherein the prevention of cell injury and/or protection of the cells is achieved in the treatment of subjects suffering from ischemic injury and/or reperfusion claim 1 , neuromodulation claim 1 , hypertension claim 1 , inflammation claim 1 , hemorrhagic shock claim 1 , hypothermia claim 1 , diabetes or edema.8. The compound of ...

Подробнее
08-08-2013 дата публикации

Nicotinic receptor non-competitive antagonists

Номер: US20130203860A1
Принадлежит: Individual

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

Подробнее
08-08-2013 дата публикации

Ionic Viscoelastics and Viscoelastic Salts

Номер: US20130204010A1
Принадлежит: Boston University

One embodiment of the present invention relates to ionic liquids and ionic viscoelastics formed between [1] a small molecule or macromolecule containing two or more cations; and [2] a small molecule or macromolecule containing two or more anions. Another embodiment of the invention is the use of the inventive ionic liquids and ionic viscoelastics, formed between a small molecule or macromolecule containing two or more cations and a small molecule or macromolecule containing two or more anions, to form a crosslinked network. In certain embodiments, the ionic liquids formed can be viscous liquids, viscous liquid formed networks, or viscoelastic networks/gels. In certain embodiments, the ionic material of the invention may be used for a variety of applications including, but not limited to, lubricants, additives, gas separation, liquid separation, membranes, fuel cells, sensors, batteries, coatings, heat storage, liquid crystals, biocompatible fluids, solvents, and electronic materials.

Подробнее
15-08-2013 дата публикации

SYNTHESIS OF BICYCLIC COMPOUNDS AND METHOD FOR THEIR USE AS THERAPEUTIC AGENTS

Номер: US20130210904A1
Принадлежит:

Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addition/cyclization sequence followed by functional group manipulation to develop functionalized compounds that can target neuraminidase, which makes them ideal candidates for treating influenza. Pharmaceutical compositions comprising the therapeutic compounds and biologically-acceptable materials are also described. Methods of inhibiting neuraminidase in subjects that are suspected of containing neuraminidase are also described. The use of metabolites of the disclosed compounds can also be used in diagnostic assays for therapeutic dosing of the disclosed compounds. 2. The compound according to where the heteroatom-containing moiety is selected from aldehyde claim 1 , acyl halide claim 1 , carbonate claim 1 , carboxyl claim 1 , carboxylate claim 1 , ether claim 1 , ester claim 1 , hydroxyl claim 1 , ketone claim 1 , silyl ether claim 1 , peroxy claim 1 , hydroperoxy claim 1 , phosphate claim 1 , phosphonate claim 1 , phosphoryl claim 1 , phosphodiester claim 1 , phosphine claim 1 , pyrrole claim 1 , thiol claim 1 , thioether/sulfide claim 1 , disulfide claim 1 , sulfonyl claim 1 , sulfonyl claim 1 , carbonothioyl claim 1 , sulfino claim 1 , sulfo claim 1 , thiocyanate claim 1 , isothiocyanate claim 1 , oxazole claim 1 , oxadiazole claim 1 , imidazole claim 1 , triazole claim 1 , tetrazole claim 1 , amine claim 1 , amide claim 1 , azide claim 1 , azo claim 1 , cyano claim 1 , isocyanate claim 1 , imide claim 1 , nitrile claim 1 , isonitrile claim 1 , nitro claim 1 , nitroso claim 1 , nitromethyl claim 1 , selenol claim 1 , guanidino claim 1 , and substituted guanidino.4. The compound according to where Vis CRR claim 3 , C(R) claim 3 , or C(R) claim 3 , and any one of R claim 3 , R claim 3 , or Rtogether with Rform a lactam or lactone.5. ...

Подробнее
15-08-2013 дата публикации

HALOGENATED DIETHYLTOLUENEDIAMINES

Номер: US20130211142A1
Принадлежит: Lonza Ltd.

Disclosed are halogenated diethyltoluenediamines of formula

Подробнее
22-08-2013 дата публикации

Monoamine compound, charge-transporting material, and organic electroluminescent device

Номер: US20130214263A1
Принадлежит: Mitsubishi Chemical Corp

The present invention provides an organic electroluminescent device exhibiting a long life, a high luminance, and a high efficiency. An organic electroluminescent device comprising on a substrate an anode, a hole transport layer, an organic light-emitting layer, and a cathode, wherein the organic light-emitting layer contains an organic compound having a pyridine ring, a pyrazine ring, or a triazine ring as a partial structure and the hole transport layer contains a monoamine compound represented by the following formula (I): wherein R 1 to R 9 represent a hydrogen atom, an aryl group, or an alkyl group; R 1 to R 9 may be the same or different from each other; and R 1 to R 9 may further have an aryl group or an alkyl group as a substituent in the case where R 1 to R 9 are an aryl group or an alkyl group.

Подробнее
22-08-2013 дата публикации

Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation

Номер: US20130217910A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a process for the preparation of substituted N-(benzyl)cyclopropanamines of the general formula (II) starting from N-[(aryl)methylene]cyclopropanamine derivatives. The present invention further provides the N-[(arypmethylene]cyclopropanamine derivatives used as starting compounds in this process according to the invention, and their use for the preparation of substituted N (benzyl)cyclopropanamines.

Подробнее
29-08-2013 дата публикации

USE OF NITROANILINE DERIVATIVES FOR THE PRODUCTION OF NITRIC OXIDE

Номер: US20130224083A1
Принадлежит: STMicroelectronics S.r.I.

The present invention relates to the use of a nitroaniline derivative of Formula I for the production of nitric oxide and for the preparation of a medicament for the treatment of a disease wherein the administration of nitric oxide is beneficial. The present invention furthermore relates to a method for the production of NO irradiating a nitroaniline derivative of Formula I, a kit comprising a nitroaniline derivative of Formula I and a carrier and to a system comprising a source of radiations and a container associated to a nitroaniline derivative of Formula I. In Formula I, R and Rare each independently hydrogen or a C-Calkyl group; Ris hydrogen or an alkyl group. 2. The kit according to claim 1 , wherein:{'sup': II', 'III', 'IV', 'V', 'VI, 'sub': 2', '18', '2', '3', '3', '3, 'Ris Ak-Y, wherein Ak is a branched or unbranched C-Calkyl group optionally substituted with —OH or NH, and Y is a tail-group selected from the group consisting of hydrogen, halogen, —SH, —S—SR, —Si(OR), —Si—X, and —CH═CRR;'}{'sup': 'III', 'Ris selected from the group consisting of alkyl group, aryl group, aralkyl group, alkenyl group, alkynyl group and heterocyclic group;'}{'sup': 'III', 'Ris an alkyl group;'}{'sup': V', 'VI, 'Rand Rare independently hydrogen or alkyl group; and'}X is halogen.3. The kit according to claim 1 , wherein said nitroaniline derivative of Formula (I) is 4-nitro-3-(trifluoromethyl)aniline.4. The kit according to claim 1 , wherein said carrier has a minor molar absorptivity in the wavelength comprised between 300 and 500 nm.5. The kit according to claim 1 , wherein said carrier is a liquid solution.6. The kit according to claim 1 , wherein said carrier is a solid substrate selected from the group consisting of a metal; an inorganic oxide; and a plastic polymeric material.7. The kit according to claim 6 , wherein said nitroaniline derivative of Formula (I) is chemically bound to said solid substrate without forming an amide bond.8. The kit according to claim 7 , ...

Подробнее
29-08-2013 дата публикации

FATTY AMINES, AMIDOAMINES, AND THEIR DERIVATIVES FROM NATURAL OIL METATHESIS

Номер: US20130225408A1
Принадлежит: STEPAN COMPANY

Fatty amine compositions made from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives are disclosed. In another aspect, fatty amidoamines made by reacting a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with an aminoalkyl-substituted tertiary amine are disclosed. The fatty amines or amidoamines are advantageously sulfonated, sulfitated, oxidized, or reduced. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin. 1. A fatty amine made from a metathesis-derived C-Cmonounsaturated acid , octadecene-1 ,18-dioic acid , or their ester derivatives.2. A derivative made by one or more of sulfonating claim 1 , sulfitating claim 1 , or oxidizing the fatty amine of .3. The fatty amine of wherein the acid or ester derivative reactant has at least 1 mole % of trans-Δunsaturation.4. The fatty amine of made by reacting the metathesis-derived acid or ester derivative with ammonia or a primary or secondary amine claim 1 , followed by reduction of the resulting fatty amide.5. The fatty amine of wherein the secondary amine is selected from the group consisting of N claim 4 ,N-dimethylamine claim 4 , N claim 4 ,N-diethylamine claim 4 , and N claim 4 ,N-diisopropylamine.6. The fatty amine of made by reducing the metathesis-derived acid or ester derivative to give a fatty alcohol claim 1 , followed by amination of the fatty alcohol.7. The fatty amine of wherein the amination is performed in a single step by reacting the fatty alcohol with ammonia or a primary or secondary amine in the presence of an amination catalyst.9. The fatty amine of wherein the ester derivative is a modified triglyceride made by self-metathesis of a natural oil.10. The fatty amine of wherein the natural oil is selected from the group consisting of soybean oil claim ...

Подробнее
29-08-2013 дата публикации

New Process for the Preparation of Aryl Substituted Olefinic Amines

Номер: US20130225827A1
Принадлежит:

An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process. 112-. (canceled)13. A process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine comprising:a1) mixing (2S)—N-(tert-butoxycarbonyl)-N-methyl-4-penten-2-amine (1 mole-equivalent) and a 5-bromo-3-alkoxypyridine (1.1 mole-equivalents) with a palladium source (0.01 mole-equivalents), a phosphine ligand (0.24 mole-equivalents) and a base (1.5 mole-equivalents) in a suitable organic solvent under an atmosphere of nitrogen; ora2) mixing N-methyl-4-penten-2-amine di-benzoyl-L-(−)-tartaric acid (1 mole-equivalent) and a 5-bromo-3-alkoxypyridine (1.1 mole-equivalents) with a palladium source (0.01 mole-equivalents), a phosphine ligand (0.24 mole-equivalents) and a base (1.5 mole-equivalents) in a suitable organic solvent under an atmosphere of nitrogen;b) adding water and heating the mixture to 90° C. for 15 to 25 h or until the appropriate level of conversion has been achieved;c) cooling the mixture and adding water and an acid, followed by stirring at 0-70° C. for 3 to 8 h;d) separating the organic solvent and the acidic aqueous phase followed by washing the aqueous phase with an organic solvent;e) adjusting the pH in the aqueous phase by the addition of a base, andf) extracting the product into the organic phase followed by separation of the organic phase; and optionallyg) treating the organic phase with a metal scavenger or charcoal to yield a (2S)-(4E)-N-methyl-5-[3-(5-alkoxypyridin)yl]-4-penten-2-amine;wherein:the aforesaid (2S)—N-(tert-butoxycarbonyl)-N-methyl-4-penten-2-amine of step a1) is prepared as follows:h) preparing 4-penten-2-ol by a process comprising:adding vinylmagnesium chloride to a mixture of copper(I) chloride and ...

Подробнее
05-09-2013 дата публикации

ADAMANTANE DERIVATIVES POSSESSING ANTI-VIRAL AND ANTI-MICROBIAL ACTIVITY

Номер: US20130231391A1
Автор: SHETTY B. Vithal
Принадлежит: Vymed Corporation

The present invention relates to adamantane derivatives that are active as antiviral and anti-microbial agents; antiviral or antibacterial compositions comprising adamantane derivatives or pharmaceutically acceptable salts thereof; and methods of preventing or treating viral or bacterial infections in mammalian hosts through the administration of adamantine derivatives or their salts or pharmaceutical compositions comprising the same. In particular, viral infections prevented or treated by the methods of the present invention may include, but are not limited to, those caused by arenavirus or one or more pox viruses, such as vaccinia and/or variola. 2. An antiviral composition which comprises:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) an effective amount of a compound of ; and'}(b) a pharmaceutically acceptable carrier.3. An antibacterial composition which comprises:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) an effective amount of a compound of ; and'}(b) a pharmaceutically acceptable carrier.4. An antiviral and antibacterial composition which comprises:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) an effective amount of a compound of ; and'}(b) a pharmaceutically acceptable carrier.5. A method for preventing or treating a bacterial infection in a mammalian host claim 1 , said method comprising administering to a mammal in need thereof an effective amount of a compound of .6. A method for preventing or treating a viral infection in a mammalian host claim 1 , said method comprising administering to mammal in need thereof an effective amount of a compound of .7. A method for preventing or treating a viral infection in a mammalian host claim 1 , wherein said viral infection is caused by vaccinia virus claim 1 , said method comprising administering to a mammal in need thereof an effective amount of a compound of .8. A method for preventing or treating a viral infection in a mammalian host claim 1 , wherein said viral infection is caused ...

Подробнее
12-09-2013 дата публикации

AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS

Номер: US20130237681A1
Автор: BURCKHARDT Urs
Принадлежит: SIKA TECHNOLOGY AG

The present invention relates to novel amides having secondary amino groups, a process for preparing them, adducts of these amines and their uses. The amides can be prepared in a simple way from readily available starting materials. They and their adducts have, in particular, a low viscosity and are suitable as constituent of polyurethane and polyurea compositions having excellent processability and high flexibility, and also as constituent of epoxy resin compositions, in particular coatings. 2. The amine of formula (I) according to claim 1 , wherein Rand Reach stand for a methyl radical and/or Rstands for a hydrogen atom.3. The amine of formula (I) according to claim 1 , wherein Rstands for a hydrogen atom or for a hydrocarbon radical with 1 to 12 carbon atoms claim 1 , optionally containing an ether oxygen.4. The amine of formula (I) according to claim 1 , wherein Rstands for a hydrogen atom or a linear or branched alkyl radical with 1 to 11 carbon atoms claim 1 , optionally with cyclic fractions and optionally with at least one heteroatom or for a mono- or polyunsaturated linear or branched hydrocarbon radical with 5 to 11 carbon atoms or for an optionally substituted aromatic or heteroaromatic six-membered ring.5. The amine of formula (I) according to claim 1 , wherein Xstands for a phenyl claim 1 , biphenyl or naphthyl radical claim 1 , where this radical is optionally substituted claim 1 , with linear or branched alkyl radicals with 1 to 6 carbon atoms claim 1 , with alkoxy groups with 1 to 6 carbon atoms claim 1 , with ester groups with 1 to 6 carbon atoms or with nitrilo groups.7. The method of synthesis of an amine of formula (I) according to claim 6 , wherein the process is carried out in such a way that at one amine PA of formula (II) is condensed with at least one aldehyde ALD of formula (III) to form an aldimine which is then hydrogenated.8. The method according to claim 6 , wherein the amine PA of formula (II) is selected from the group consisting of 1 ...

Подробнее
26-09-2013 дата публикации

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES

Номер: US20130251654A1
Принадлежит:

The present invention relates to a pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or hypermelanosis, comprising: (a) a pharmaceutically effective amount of an indatraline derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The composition of the present invention effectively induces autophagy of cells, and thus is very effective for preventing or treating autophagy-related diseases. In addition, the composition of the present invention inhibits angiogenesis through the mechanism of inhibiting angiogenesis, invasion and metastasis and inhibits melanogenesis, and thus can also be effective for preventing or treating angiogenic diseases or melanin-related diseases. 110-. (canceled)12. The method according to claim 11 , wherein each of R claim 11 , Rand Ris independently hydrogen or C-Calkyl claim 11 , and each of Rto Ris independently hydrogen claim 11 , C-Calkyl or halogen.14. The method according to claim 13 , wherein each of Xand Xis chlorine atom (Cl).15. The method according to claim 11 , wherein the autophagy-related disease is selected from the group consisting of cancer claim 11 , atherosclerosis claim 11 , Alzheimer's disease claim 11 , Parkinson's disease claim 11 , amyotrophic lateral sclerosis claim 11 , Huntington's disease claim 11 , spinocerebellar ataxia claim 11 , oculopharyngeal muscular dystrophy claim 11 , prion disease claim 11 , Fatal familial insomnia claim 11 , alpha-1-antitrypsin deficiency claim 11 , dentatorubral pallidoluysian atrophy claim 11 , frontotemporal dementia claim 11 , progressive supranuclear palsy claim 11 , x-linked spinobulbar muscular atrophy and neuronal intranuclear hyaline inclusion disease.16. The method according to claim 11 , wherein the angiogenic disease is selected from the group consisting of cancer claim 11 , stenosis claim 11 , restenosis claim 11 , diabetic retinopathy claim 11 , retinopathy of prematurity ...

Подробнее
26-09-2013 дата публикации

Compounds And Methods For Treating Candidiasis And Aspergillus Infections

Номер: US20130252964A1
Принадлежит: POLYMEDIX, INC.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a or species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an infection. 2. The method of wherein each X is S.3. The method of wherein each Ris claim 1 , independently claim 1 , —CH claim 1 , —(CH)—NH claim 1 , —(CH)—NH—C(═NH)NH claim 1 , or —(CH)—NH—C(═O)—R claim 1 , where each n is claim 1 , independently claim 1 , 1 or 2 claim 1 , and each Ris claim 1 , independently claim 1 , H or methyl.49-. (canceled)10. The method of wherein each Ris CF.11. The method of wherein each Vis H and each Vis claim 1 , independently claim 1 , —N—C(═O)—R claim 1 , where each Ris claim 1 , independently claim 1 , —(CH)—NHor —(CH)—NH—C(═NH)NH claim 1 , where each n is claim 1 , independently claim 1 , 1 to 4.1218-. (canceled)19. The method of wherein each Vis H and each Vis —S—R claim 1 , where each Ris —(CH)—NHwhere each n is 2.20. The method of wherein each Ris H claim 1 , —S—(CH)—NH claim 1 , or —S—(CH)—NH—C(═NH)NH claim 1 , where each m is claim 1 , independently claim 1 , 1 to 4.2123-. (canceled)24. The method of wherein:each X is S;{'sup': '1', 'sub': 2', 'n', '2', '2', 'n', '2, 'each Ris, independently, —(CH)—NHor —(CH)—NH—C(═NH)NH, where each n is, independently, 1 to 4;'}{'sup': '2', 'sub': 3', '3', '3, 'each Ris, independently, halo, CF, or C(CH); and'}{'sup': 1', '2', '5', '5, 'sub': 2', 'n', '2, 'each Vis H and each Vis, independently, —S—R, where each Ris, independently, —(CH)—NH, where each n is, independently, 1 to 4.'}2532-. (canceled)3553-. (canceled)5576-. (canceled)7880-. (canceled)82122-. (canceled)124159-. (canceled)161179-. (canceled)181198-. (canceled)200218-. (canceled)220237-. (canceled)239243-. (canceled)245252-. (canceled) The present disclosure was supported by funds from the U.S. Government (NIH/NIDCR Grant No. 2R44DE018371-02) and the U.S. Government may therefore have certain rights in the ...

Подробнее
26-09-2013 дата публикации

STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

Номер: US20130253064A1
Принадлежит:

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. 184.-. (canceled)86. The method of claim 85 , wherein Rand Rare each independently hydrogen claim 85 , halogen claim 85 , alkyl or —OR; and Rand Rare each independently hydrogen claim 85 , halogen claim 85 , alkyl or —OR claim 85 , wherein each Ris independently selected from hydrogen or alkyl.87. The method of claim 85 , wherein:t is 2 or 3;{'sup': '20', 'two adjacent R, together with the two carbon atoms to which they are attached, form a fused phenyl ring; and'}{'sup': 3', '4', '5', '6, 'R, R, Rand Rare each independently hydrogen, alkyl, halogen or fluoroalkyl.'}88. The method of claim 87 , wherein Rand Rare each independently hydrogen claim 87 , halogen claim 87 , alkyl or —OR; and Rand Rare each independently hydrogen claim 87 , halogen claim 87 , alkyl or —OR.90. The method of wherein each of Rand Ris hydrogen.91. The method of wherein:p is 0, 1, 2 or 3; and{'sup': '21', 'each Ris independently alkyl, halogen or fluoroalkyl.'}92. The method of claim 91 , wherein Rand Rare each independently hydrogen claim 91 , halogen claim 91 , alkyl claim 91 , fluoroalkyl claim 91 , —ORor —NRR; and Rand Rare each independently hydrogen claim 91 , halogen claim 91 , alkyl claim 91 , fluoroalkyl claim 91 , or —OR claim 91 , wherein each Ris independently hydrogen or alkyl; and{'sup': 18', '19, 'each Rand Rare independently hydrogen or alkyl.'}93. The method of wherein Ris alkyl and Ris hydrogen.94. The method of claim 93 , wherein Rand Rare each independently hydrogen claim 93 , halogen claim 93 , alkyl ...

Подробнее
26-09-2013 дата публикации

PROCESS FOR THE PRODUCTION OF AMIDES

Номер: US20130253225A1
Принадлежит:

The present invention relates to a process for the preparation of compounds of formula I 2. A compound of formula IV according to claim 1 , wherein Rand Rare methyl.4. A compound of formula IV prepared by the process of . This application is a divisional application of U.S. Ser. No. 13/198,739 filed Jan. 8, 2013, which is a divisional application of U.S. Ser. No. 12/066,683 filed Jul. 16, 2008, which is a 371 of International Application No. PCT/EP2006/008982 filed Sep. 14, 2006, which claims priority to CH 01520/05 filed Sep. 16, 2005 and CH 0296/06 filed Feb. 24, 2006, the contents of which are incorporated herein by reference.The present invention relates to a process for the preparation of pyrazolyl-4-carboxylic acid benzo-norbornen-5-yl-amides and also to novel intermediates for use in such a process. The present invention further relates to a novel crystal modification of syn-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide, compositions comprising it and to the use thereof in the control of fungus infestation in cultivated plants.Pyrazolyl-4-carboxylic acid benzonorbornen-5-yl-amides, for example 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide, are valuable fungicides, such as are described, for example, in WO 04/035589.WO 04/035589 describes a process for the preparation of pyrazolyl-4-carboxylic acid benzonorbornen-5-yl-amides (see Scheme 1):According to WO 04/035589, a 3-nitro-dehydrobenzene generated, for example, from 6-nitro-anthralinic acids of formula (A) wherein Rand Rmay be, inter alia, hydrogen, is first reacted in a Diels-Alder reaction with a cyclic 1,4-diene of formula (B) wherein R, R, Rand Rmay be, inter alia, hydrogen and Y may be, inter alia, —CH((i)-CH)—, to form a 5-nitro-benzonorbornadiene compound of formula (C). Subsequent catalytic reduction under standard conditions (for example, Ra/Ni or ...

Подробнее
10-10-2013 дата публикации

COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF

Номер: US20130267543A1
Принадлежит:

The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity. 129.-. (canceled)33. The method of wherein the disease is caused by mis-folded proteins.34. The method of claim 30 , wherein the disease is Huntington's disease claim 30 , Parkinson's disease claim 30 , Alzheimer's disease claim 30 , or Amyotropic Lateral Sclerosis.35. The method of claim 30 , wherein the pharmaceutical formulation can be administered orally claim 30 , intranasally claim 30 , buccally claim 30 , topically claim 30 , sublingually claim 30 , rectally claim 30 , vaginally claim 30 , parenterally (including subcutaneous claim 30 , intramuscular claim 30 , intravenous and intradermal) claim 30 , transdermally claim 30 , or by inhalation claim 30 , and may take the form of tablet claim 30 , lozenge claim 30 , granules claim 30 , patche claim 30 , capsule claim 30 , ampoules claim 30 , suppositories claim 30 , or aerosol. This application claims priority to U.S. patent application Ser. No. 12/945,522, filed Nov. 12, 2010, which is a continuation-in-part of International Patent Application No. PCT/US2009/044186, filed May 15, 2009, published Nov. 19, 2009 as WO 2009/140621, which claims priority to U.S. Provisional Patent Application No. 61/053,513, filed May 15, 2008.This invention was made with government support under Grant Nos. GM059911-08 and GM076954 awarded by the National Institutes of Health. The government has certain rights in the invention.The present invention relates ...

Подробнее
10-10-2013 дата публикации

TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS

Номер: US20130267571A1
Принадлежит: NeuroQuest Inc.

The present application provides a terpene analogue of Formula (I) or a pharmaceutically acceptable isomer, salt or ester thereof, and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain. These terpene analogues can also be used to treat other electrical disorders in the central and peripheral nervous system. Also provided are methods of synthesizing the terpene analogues of Formula I. 2. The method of claim 1 , wherein Y is CH claim 1 , W is CH claim 1 , and X is O—CH claim 1 , O—CH-aryl claim 1 , NH claim 1 , N(H)—CH claim 1 , N—(CH) claim 1 , N(H)—C(═O)-aryl claim 1 , N(H)—C(═O)—CH claim 1 , N(H)—C(═O)-aryl(OH) claim 1 , SOMe claim 1 , or SOMe.3. The method of claim 1 , wherein Y is C═O and X is H claim 1 , OH claim 1 , NHN(H)—CH claim 1 , N—(CH) claim 1 , N(H)-aryl claim 1 , N(Me)OMe claim 1 , N(Me)OH claim 1 , or CF.5. The method of claim 1 , wherein:Y is absent;{'sub': 3', '3', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'X is —C(═O)H, —C(═O)CF—COOH, —CH(OH)CF, —C(OH)(CF), —C(═O)N(Me)OMe, C(═O)N(Me)OH, —CONHAryl, —CONH, —CONHAlkyl, —CON(Alkyl)—SOAryl, —SOalkyl, SOalkyl, —SONHAryl, —SON(Aryl), —SON(Alkyl), —SONHalkyl, or SONH; and'}{'sub': 1', '20, 'W is H, a substituted or unsubstituted Cto Calkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted alkylaryl.'}6. The method of claim 1 , wherein the terpene analogue is selected from the group consisting of:(E)-1-methoxy-3,7-dimethylocta-2,6-diene,(E)-((3,7-dimethylocta-2,6-dienyloxy)methyl)benzene,3,7-dimethyloct-2,6-dienoic acid,N,3,7-trimethylocta-2,6-dienamide,(E)-3,7-dimethylocta-2,6-dien-1-amine,(E)-N-(3,7-dimethylocta-2,6-dienyl)benzamide,(E)-3,7-dimethylocta-2,6-dienal,(E)-3,7-dimethylocta-2,6-dienoic acid,(E)-N-(3,7-dimethylocta-2,6-dienyl)acetamide,(E)-3,7-dimethyl-N-phenylocta-2,6-dienamide,(E)-N-(3,7-dimethylocta-2,6-dienyl)-2-hydroxybenzamide,(E)-N,N,3,7-tetramethylocta-2,6-dienamide,(E)-N,N,3,7- ...

Подробнее
10-10-2013 дата публикации

Bisamineazaallylic Ligands And Their Use In Atomic Layer Deposition Methods

Номер: US20130267709A1
Принадлежит:

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands. 2. The metal complex of claim 1 , wherein L is a bisamineazaallylic ligand.4. The metal complex of wherein L is halogen or methyl.5. The metal complex of prepared by a method comprising:{'sub': 1', '2', '2', '3', '4', '2', '2', '2', '1', '2', '2', '2', '2', '3', '4, 'a) reacting an aldehyde compound having a formula RRN—CH—COH with a compound having a formula RRN—CHCHNHto form a reaction product represented by formula RRN—CH—CH═N—CH—CH—NRR;'}b) treating the reaction product with lithium hexamethyldisilazide (LHMDS) to produce a ligand coordinated with a lithium ion, and;c) forming the transition metal complex by reacting the ligand coordinated with the lithium ion and a transition metal halide. This application is a divisional under 35 U.S.C. §121 of U.S. application Ser. No. 13/189,644, filed Jul. 25, 2011, which claims priority to U.S. Provisional Application Ser. No. 61/407,970, filed Oct. 29, 2010 the disclosures of which are hereby incorporated by reference in their entirety.The present invention relates generally to methods of depositing thin films of elemental metal and to metal coordination complexes useful in such methods. In particular, the invention relates to coordination complexes of metal cations with multidentate azaallylic ligands and their use in atomic layer deposition processes.Deposition of thin films on a substrate surface is an important process in a variety of industries including semiconductor processing, diffusion barrier coatings and dielectrics for magnetic read/write heads. In the semiconductor industry, in particular, miniaturization requires atomic level control of thin film deposition to produce conformal coatings on high aspect structures. One method ...

Подробнее
17-10-2013 дата публикации

Compound for organic light-emitting diode and organic light-emitting diode including the same

Номер: US20130270524A1
Принадлежит: Samsung Display Co Ltd

A compound represented by Formula 1 below may be used in an organic light emitting diode.

Подробнее
24-10-2013 дата публикации

P-terphenyl compound mixture and electrophotographic photoreceptors made by using the same

Номер: US20130280652A1
Принадлежит: Hodogaya Chemical Co Ltd

An object of the invention is to provide a method of making a p-terphenyl compound mixture which includes two symmetric p-terphenyl compounds respectively represented by formula (1) and formula (2) and an asymmetric p-terphenyl compound represented by formula (3)

Подробнее
31-10-2013 дата публикации

CYCLOPROPYLAMINE INHIBITORS OF OXIDASES

Номер: US20130289076A1
Принадлежит:

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer. 24-. (canceled)5. The compound of wherein G is aryl or heteroaryl.6. The compound of wherein G is phenyl claim 5 , indolyl or indazolyl.79-. (canceled)10. The compound of claim 1 , wherein G is phenyl.11. The compound of claim 1 , wherein E is —X═X—.12. The compound of wherein one of X claim 11 , X claim 11 , X claim 11 , and Xis N or C(R2) and the other ones of X claim 11 , X claim 11 , X claim 11 , and Xare each independently C(R2).13. The compound of claim 11 , wherein one of X claim 11 , X claim 11 , Xand Xis N and the other ones of X claim 11 , X claim 11 , Xand Xare each independently C(R2).14. The compound of wherein Xis N claim 13 , and X claim 13 , Xand Xare each independently C(R2).15. (canceled)16. The compound of claim 1 , wherein each R1 is independently chosen from lower alkyl claim 1 , lower alkynyl claim 1 , amido claim 1 , halo claim 1 , lower haloalkyl claim 1 , cyano claim 1 , hydroxyl claim 1 , or alkoxy.1718-. (canceled)19. The compound of claim 1 , wherein each R2 is —H.20. The compound of claim 1 , wherein n is 0 or 1.21. (canceled)22. The compound of claim 1 , wherein the compound of Formula (I) is in the trans configuration in respect of the substituents on the cyclopropyl ring.23. The compound of claim 1 , wherein said compound is chosen from:5-((trans)-2-aminocyclopropyl)-N-(3-chlorophenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(4-chlorophenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(4-(trifluoromethyl)phenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(3-methoxyphenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-(4-methoxyphenyl)pyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-p-tolylpyridin-2-amine;5-((trans)-2-aminocyclopropyl)-N-m-tolylpyridin-2-amine;4-(5-((trans)-2-aminocyclopropyl)pyridin-2-ylamino ...

Подробнее
07-11-2013 дата публикации

Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions

Номер: US20130296346A1
Принадлежит: Faes Farma SA

The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases.

Подробнее
14-11-2013 дата публикации

Organic compound, organic electroluminescence element, and image display device

Номер: US20130300638A1
Принадлежит: Canon Inc

The present invention provides an organic electroluminescence element having a high luminous efficiency. An organic electroluminescence element includes an anode, a cathode, and at least one organic compound layer disposed between the anode and the cathode, wherein at least one of the at least one the organic compound layer contains an organic compound shown in Claim 1.

Подробнее
28-11-2013 дата публикации

PROCESS FOR THE PREPARATION OF ROTIGOTINE

Номер: US20130317255A1
Принадлежит: FIDIA FARMACEUTICI S.p.A.

A process for the preparation of Rotigotine (1) 1. 2-N-Propyl-5-hydroxy tetraline hydrobromide 5 This application is a divisional application of U.S. Ser. No. 13/120,682 filed on Jun. 13, 2011 which a U.S. national stage of PCT/IB2009/006934 filed on Sep. 24, 2009 which claims priority to and the benefit of Italian Application No. MI2008A1713 filed on Sep. 26, 2008, the contents of which are incorporated herein by reference in their entirety.The present invention relates to 5,6,7,8-tetrahydro-6-S-[N-propyl-2-(2-thienyl)-N-ethyl]amino-1-naphthalenol, commonly known as Rotigotine (1), a medicament used in the therapy of the early stages of idiopathic Parkinson's disease, usually in the form of its hydrochloride salt.The preparation and therapeutical uses of Rotigotine were first disclosed in U.S. Pat. No. 4,564,628 and U.S. Pat. No. 4,885,308. The product currently pharmaceutically used is the S enantiomeric form or its hydrochloride salt, the known syntheses of which involve 2-N-propyl-5-methoxy tetraline S enantiomer (2) as the key intermediatewhich is prepared by optical resolution of the racemate according to what described in U.S. Pat. No. 4,968,837.A number of procedures for the transformation of amine 2 into Rotigotine are disclosed. Among them, a procedure involves heating 2 in xylene with 2-thienylacetic acid and the trimethylamine-borane complex (U.S. Pat. No. 4,564,628 and 1985, 7, 208-211), which affords 5,6,7,8-tetrahydro-6-S-[N-propyl-2-(2-thienyl)-N-ethyl]amino-1-methoxynaphthalene 3.The trimethylamine-borane complex is an expensive, flammable product; therefore, this method for linking the thienylacetic chain to the secondary nitrogen of 2 is industrially problematic, due to the known instability of boron hydrides at high temperatures.Transformation of 3 into Rotigotine, which is reported in the patents cited above and consists in hydrolyzing the methyl ether to free the phenol group, is carried out by treatment with boron tribromide at low temperature ...

Подробнее
05-12-2013 дата публикации

Zinc oxide film-forming composition, zinc oxide film production method, and zinc compound

Номер: US20130323413A1
Принадлежит: Adeka Corp

Disclosed are a composition for forming a zinc oxide-based film, said composition containing, as an essential component, a zinc compound represented by the following formula (1): wherein R 1 and R 2 mutually independently represent an alkyl group having 1 to 4 carbon atoms, a process for producing the zinc oxide-based film, and the zinc compound. The composition makes it possible to form a high-quality zinc oxide-based film, which has transparency, homogeneity and electrical conductivity, at a low temperature of 300° C. or lower.

Подробнее
12-12-2013 дата публикации

COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

Номер: US20130328021A1
Принадлежит: Samsung Display Co., Ltd.

Embodiments of the present disclosure are directed to a compound represented by Formula 1, and to organic light-emitting diodes including the compound. 2. The compound of claim 1 , wherein:{'sub': 1', '2', '1', '30', '5', '30', '3', '30', '6', '30, 'Rand Rare each independently a halogen group, a cyano group, a substituted or unsubstituted C-Calkyl group, a substituted or unsubstituted C-Caryl group, a substituted or unsubstituted C-Cheteroaryl group, or a substituted or unsubstituted C-Ccondensed polycyclic group;'}{'sub': 3', '5', '30', '3', '30', '6', '30, 'Ris hydrogen, deuterium, a halogen group, a cyano group, a substituted or unsubstituted C-Caryl group, a substituted or unsubstituted C-Cheteroaryl group, or a substituted or unsubstituted C-Ccondensed polycyclic group;'}{'sub': 6', '10', '2', '11, 'A is a linking group such as a substituted or unsubstituted C-Carylene group, a substituted or unsubstituted C-Cheteroarylene group, or a linking group in which at least two arylene groups and/or heteroarylene groups are linked; and'}{'sub': 1', '2', '5', '30', '3', '30', '6', '30, 'Arand Arare each independently a substituted or unsubstituted C-Caryl group, a substituted or unsubstituted C-Cheteroaryl group, or a substituted or unsubstituted C-Ccondensed polycyclic group.'}7. The compound of claim 1 , wherein Rand Rcombine to form a ring.9. An organic light-emitting diode comprising:a first electrode;a second electrode; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an organic layer between the first electrode and the second electrode, wherein the organic layer comprises the compound according to .'}10. The organic light-emitting diode of claim 9 , wherein the organic layer is a hole injection layer claim 9 , a hole transport layer claim 9 , or a functional layer having both hole injection and hole transport abilities.11. The organic light-emitting diode of claim 9 , wherein the organic layer is a hole transport layer or a hole injection layer.12. The ...

Подробнее
19-12-2013 дата публикации

COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Номер: US20130336890A1
Принадлежит: PIRAMAL IMAGING SA

This invention relates to novel compounds suitable as precursors for the preparation of certain F labelled positron emission tomography (PET) tracers. Furthermore the invention relates to the preparation of such precursor molecules and to the preparation of PET tracers by F labelling of such precursors. 2. A compound according to claim 1 , wherein Ris selected from the group consisting of chloro claim 1 , bromo claim 1 , methanesulfonyloxy claim 1 , and p-toluenesulfonyloxy.3. A compound according to claim 1 , whereinD is deuterium;{'sup': '1', 'Ris methyl; and'}{'sup': '2', 'Ris selected from fluoro or chloro.'}7. A according to claim 1 , wherein said compound is an [F] labelled compound.8. A diagnostic composition for PET imaging comprising a [F] labelled compound according to .9. A method of diagnostic PET imaging comprising subjecting a patient to diagnostic PET imaging of CNS diseases claim 7 , wherein said patient has been administered an [F] labelled compound according to .10. A method of diagnostic PET imaging comprising subjecting a patient to diagnostic PET imaging of CNS diseases claim 8 , wherein said patient has been administered a diagnostic composition according to .11. A method according to claim 9 , wherein said patient is imaged for Alzheimer's disease.15. A method according to claim 14 , wherein the sulfonyl chloride is methanesulfonyl chloride.20. A kit comprising at least one sealed container comprising a compound according to .21. A kit comprising at least one sealed container comprising a compound of .22. A kit according to claim 20 , further comprising a further sealed container comprising reagents. This invention relates to novel compounds suitable for labelling or already labelled by F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).Molecular imaging has ...

Подробнее
26-12-2013 дата публикации

Synthesis Of Triethylenetetramines

Номер: US20130345311A1
Принадлежит: PHILERA NEW ZEALAND LIMITED

Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity. 175.-. (canceled)76. An isolated triethylenetetramine hydrochloride salt that has a purity of greater than about 95% pure.77. The isolated triethylenetetramine hydrochloride salt of wherein the salt is a triethylenetetramine dihydrochloride salt.78. The isolated triethylenetetramine hydrochloride salt of that has a purity of greater than about 96% pure.79. The isolated triethylenetetramine hydrochloride salt of wherein the salt is a triethylenetetramine dihydrochloride salt.80. The isolated triethylenetetramine hydrochloride salt of that has a purity of greater than about 97% pure.81. The isolated triethylenetetramine hydrochloride salt of wherein the salt is a triethylenetetramine dihydrochloride salt.82. The isolated triethylenetetramine hydrochloride salt of that has a purity of greater than about 98% pure.83. The isolated triethylenetetramine hydrochloride salt of wherein the salt is a triethylenetetramine dihydrochloride salt.84. The isolated triethylenetetramine hydrochloride salt of that has a purity of greater than about 99% pure.85. The isolated triethylenetetramine hydrochloride salt of wherein the salt is a triethylenetetramine dihydrochloride salt.86. The isolated triethylenetetramine hydrochloride salt of that has a purity of about 100% pure.87. The isolated triethylenetetramine hydrochloride salt of wherein the salt is a triethylenetetramine dihydrochloride salt.88. A pharmaceutical composition comprising substantially pure triethylenetetramine dihydrochloride and a pharmaceutically acceptable excipient.89. The pharmaceutical composition of wherein the substantially pure triethylenetetramine dihydrochloride has a purity of greater than about 95% pure.90. An isolated triethylenetetramine salt that has a purity of greater than about 99% pure and is ...

Подробнее
02-01-2014 дата публикации

POLYISOBUTYLENES AND PROCESS FOR MAKING SAME

Номер: US20140005349A1
Принадлежит: THE UNIVERSITY OF AKRON

The present invention generally relates to alcohol-terminated polyisobutylene (PIB) compounds, and to a process for making such compounds. In one embodiment, the present invention relates to primary alcohol-terminated polyisobutylene compounds, and to a process for making such compounds. In still another embodiment, the present invention relates to polyisobutylene compounds that can be used to synthesize polyurethanes, to polyurethane compounds made via the use of such polyisobutylene compounds, and to processes for making such compounds. In yet another embodiment, the present invention relates to primary alcohol-terminated polyisobutylene compounds having two or more primary alcohol termini and to a process for making such compounds. In yet another embodiment, the present invention relates to primary terminated polyisobutylene compounds having two or more primary termini selected from amine groups or methacrylate groups. 1. A primary alcohol-terminated polyisobutylene compound according to the following formula:{'br': None, 'sub': 3', '2', '2', '3', '2', 'n, '˜˜˜C(CH)—[CH—C(CH)]—R—OH'}{'sub': 3', '12', '3', '12, 'where ˜˜˜ represents the remaining portion of a linear, star, hyperbranched, or arborescent molecule, n is an integer from 2 to about 5,000, and R is a straight Cto Clinkage formed from a corresponding straight Cto Callyl group having a double bond present at the end of the allyl group, and where the primary alcohol-terminated polyisobutylene has at least two primary alcohol termini.'}2. The primary alcohol-terminated polyisobutylene compound of claim 1 , wherein n is an integer from about 7 to about 4 claim 1 ,500.3. The primary alcohol-terminated polyisobutylene compound of claim 1 , wherein n is an integer from about 100 to about 2 claim 1 ,000.4. The primary alcohol-terminated polyisobutylene compound of claim 1 , wherein n is an integer from about 250 to about 1 claim 1 ,500.5. A method for producing a primary methacrylate-terminated polyisobutylene ...

Подробнее
02-01-2014 дата публикации

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Номер: US20140005384A1
Принадлежит: PFIZER INC

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Подробнее
09-01-2014 дата публикации

SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS

Номер: US20140011857A1
Принадлежит: THE JOHNS HOPKINS UNIVERSITY

The invention provides for novel compounds which are inhibitors of lysine-specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer. 3. The compound of claim 2 , wherein J is O.4. The compound of claim 2 , wherein q is 1.5. The compound of claim 2 , wherein Ris nitro claim 2 , hydroxy claim 2 , thio claim 2 , C(O)NRR claim 2 , or C(O)OR.6. The compound of claim 5 , wherein Ris nitro claim 5 , hydroxy claim 5 , thio claim 5 , C(O)NH claim 5 , or C(O)OEt.7. The compound of claim 1 , wherein Y is —NH.8. The compound of claim 7 , wherein J is absent claim 7 , and the carbon to which J is attached is —CH—.9. The compound of claim 7 , wherein q is 3 or 4.10. The compound of claim 7 , wherein Ris nitro claim 7 , hydroxy claim 7 , thio claim 7 , C(O)NRR claim 7 , or C(O)OR.11. The compound of claim 7 , wherein Ris haloalkyl claim 7 , nitro claim 7 , hydroxy claim 7 , thio claim 7 , C(O)NRR claim 7 , or C(O)OR.12. The compound of claim 7 , wherein Ris haloalkyl claim 7 , nitro claim 7 , hydroxy claim 7 , thio claim 7 , C(O)NRR claim 7 , or C(O)OR.14. (canceled)1618-. (canceled)20. A pharmaceutical composition comprising a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt claim 1 , solvate or hydrate thereof thereof claim 1 , in combination with a pharmaceutically acceptable carrier or excipient.21. (canceled)24. The method of claim 22 , wherein the disease or disorder is selected from: tumor claim 22 , cancer claim 22 , blood disorder claim 22 , neoplasia claim 22 , skin disorders claim 22 , neovascularization claim 22 , inflammatory and arthritic diseases claim 22 , retinoblastoma claim 22 , cystoid macular edema (CME) claim 22 , exudative age-related macular degeneration (AMD) claim 22 , diabetic retinopathy claim 22 , diabetic macular edema claim 22 , or ocular inflammatory disorders.2528-. (canceled)3031-. (canceled)33. The method of claim 32 , wherein the compound inhibits LSD1 to thereby treat ...

Подробнее
09-01-2014 дата публикации

METHOD FOR PRODUCING CYCLIC SILANE COMPOUND OR SALT THEREOF, SALT HAVING CYCLIC SILANE DIANION, AND CYCLIC SILANE DIANION SALT-CONTAINING COMPOSITION

Номер: US20140012030A1
Принадлежит:

An object of the present invention is to provide a production method that can efficiently produce a cyclic silane compound or a salt thereof with a high yield and to provide a novel salt having a cyclic silane dianion that is easy to handle and a cyclic silane dianion salt-containing composition. The method for producing a cyclic silane compound or a salt thereof of the present invention includes the step of allowing a halosilane compound to react in the presence of at least one of a phosphonium salt and an ammonium salt, and a compound represented by a specific formula. 2. The method for producing a cyclic silane compound or a salt thereof according to claim 1 , wherein the reaction is carried out in the presence of a basic compound.3. The method for producing a cyclic silane compound or a salt thereof according to claim 1 , wherein the phosphonium salt or the ammonium salt is a quaternary phosphonium salt or a quaternary ammonium salt.7. The cyclic silane dianion salt-containing composition according to claim 6 , wherein the salt having a cyclic silane dianion represented by the general formula (vii) is contained in an amount of 1 to 10000 parts by mass claim 6 , based on the total amount of 100 parts by mass of the salt having a cyclic silane dianion represented by the general formula (vi).8. The method for producing a cyclic silane compound or a salt thereof according to claim 2 , wherein the phosphonium salt or the ammonium salt is a quaternary phosphonium salt or a quaternary ammonium salt. (1) Field of the InventionThe present invention relates to a production method that can efficiently obtain a cyclic silane compound or a salt thereof by a simple method, a novel salt having a cyclic silane dianion, and a cyclic silane dianion salt-containing composition.(2) Description of Related ArtA silane compound is widely utilized as a raw material of silicon and silica, and a water-reactive combustible gas such as monosilane and disilane is mostly used. On the other ...

Подробнее
23-01-2014 дата публикации

INHIBITORS OF THE INFLUENZA A VIRUS M2 PROTON CHANNEL

Номер: US20140024635A1

Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. 2. The compound according to wherein X and Y are each independently methylene or ethylene.3. The compound according to wherein X is methylene and Y is ethylene.4. The compound according to wherein at least one of Rand Ris hydrogen.5. The compound according to wherein one of Rand Ris carbonyl claim 4 , amino claim 4 , carboxyl claim 4 , cyano claim 4 , or —CH(R)(R).6. The compound according to wherein n is 1 or 2 claim 5 , except that if n is 1 claim 5 , both X and Y are methylene claim 5 , and both Rand Rare hydrogen claim 5 , then one of Rand Ris not carbonyl.7. The compound according to wherein one of Rand Ris —CH(R)(R).8. The compound according to wherein one of Rand Ris amino10. A composition comprising a compound according to and a pharmaceutically acceptable carrier claim 1 , diluent claim 1 , or excipient. This application is a divisional of U.S. Ser. No. 12/848,197, filed Aug. 1, 2010 (now allowed), the entire contents of which are hereby incorporated herein by reference.The present invention pertains to, among other things, compounds and methods for modulating the activity of the influenza virus.The M2 protein is found in the viral envelope of influenza A virus and functions as a highly selective, pH-regulated proton channel important for the life cycle of the virus. Unlike neuraminidase inhibitors, rimantadine and amantadine are anti-viral agents capable of blocking the tetrameric M2 channel. In 2006, the CDC issued an alert instructing clinicians to avoid using M2 ion-channel inhibitors during influenza season due to the extraordinarily high frequency of amantadine resistance in ...

Подробнее
23-01-2014 дата публикации

Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Номер: US20140024679A1
Принадлежит: Reviva Pharmaceuticals Inc

The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Подробнее
30-01-2014 дата публикации

CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

Номер: US20140027721A1
Принадлежит: Samsung Display Co., Ltd.

Embodiments of the invention are directed to a condensed-cyclic compound represented by Formula 1, and to an organic light-emitting device including the condensed-cyclic compound. 2. The condensed-cyclic compound of claim 1 , wherein Arand Arare each independently one of a substituted or unsubstituted phenyl group claim 1 , a substituted or unsubstituted biphenyl group claim 1 , a substituted or unsubstituted terphenyl group claim 1 , a substituted or unsubstituted naphthyl group claim 1 , a substituted or unsubstituted phenoxy group claim 1 , a substituted or unsubstituted fluorenyl group claim 1 , a substituted or unsubstituted spiro-fluorenyl group claim 1 , a substituted or unsubstituted phenanthrenyl group claim 1 , a substituted or unsubstituted pyranyl group claim 1 , a substituted or unsubstituted pyridyl group claim 1 , a substituted or unsubstituted pyrimidinyl group claim 1 , a substituted or unsubstituted diazinyl group claim 1 , a substituted or unsubstituted triazinyl group claim 1 , a substituted or unsubstituted quinolyl group claim 1 , a substituted or unsubstituted benzoimidazolyl group claim 1 , a substituted or unsubstituted benzoxazolyl group claim 1 , a substituted or unsubstituted pentalenyl group claim 1 , a substituted or unsubstituted indenyl group claim 1 , a substituted or unsubstituted azulenyl group claim 1 , a substituted or unsubstituted heptalenyl group claim 1 , a substituted or unsubstituted indacenyl group claim 1 , a substituted or unsubstituted acenaphthyl group claim 1 , a substituted or unsubstituted phenalenyl group claim 1 , a substituted or unsubstituted phenanthridinyl group claim 1 , a substituted or unsubstituted anthryl group claim 1 , a substituted or unsubstituted fluoranthenyl group claim 1 , a substituted or unsubstituted triphenylenyl group claim 1 , a substituted or unsubstituted pyrenyl group claim 1 , a substituted or unsubstituted chrysenyl group claim 1 , a substituted or unsubstituted naphthacenyl group claim ...

Подробнее
06-02-2014 дата публикации

SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS

Номер: US20140038987A1
Принадлежит:

The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases. 2. The compound according to claim 1 , wherein n is 1.3. The compound according to claim 1 , wherein n is 2.4. The compound according to claim 1 , wherein Y is N.5. The compound according to claim 1 , wherein Y is CR.6. The compound according to claim 5 , wherein Ris H or C-Chaloalkyl.7. The compound according to claim 5 , wherein Ris H or trifluoromethyl.8. The compound according to claim 1 , wherein Ris selected from the group consisting of H claim 1 , cyano claim 1 , C-Chaloalkoxy and C-Chaloalkyl.9. The compound according to claim 1 , wherein Ris selected from the group consisting of H claim 1 , cyano claim 1 , trifluoromethoxy and trifluoromethyl.10. The compound according to claim 1 , wherein Ris selected from the group consisting of H claim 1 , C-Calkoxy claim 1 , C-Calkyl claim 1 , C-Calkylamino claim 1 , C-Calkylsulfonyl claim 1 , C-Calkylthio claim 1 , carboxamide claim 1 , cyano claim 1 , C-Ccycloalkoxy claim 1 , C-Ccycloalkyl claim 1 , C-Chaloalkoxy claim 1 , C-Chaloalkyl claim 1 , halogen claim 1 , heteroaryl and heterocyclyl claim 1 , wherein said C-Calkyl and C-Calkoxy are each optionally substituted with one or two substituents selected from C-Ccycloalkyl and halogen.11. The compound according to claim 1 , ...

Подробнее
06-02-2014 дата публикации

METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES

Номер: US20140039048A1
Принадлежит: Acucela Inc.

Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions. 2. (canceled)3. (canceled)4. The method of claim 1 , wherein n is 0 claim 1 , 1 claim 1 , or 2.5. (canceled)6. (canceled)7. The method of claim 4 , wherein X is —C(R)—O—.8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. The method of claim 7 , wherein Y is substituted or unsubstituted carbocyclyl claim 7 , or substituted or unsubstituted C-Calkyl.13. The method of claim 12 , wherein Y is substituted or unsubstituted carbocyclyl.14. The method of claim 12 , wherein Y is substituted or unsubstituted C-Calkyl.15. The method of claim 13 , wherein the substituted or unsubstituted carbocyclyl is a substituted or unsubstituted 4- claim 13 , 5- claim 13 , 6- claim 13 , or 7-membered ring.16. The method of claim 14 , wherein the substituted or unsubstituted C-Calkyl is a substituted or unsubstituted C-Calkyl.17. The method of claim 16 , wherein the substituted C-Calkyl is substituted with an C-Calkoxy group.18. The method of claim 18 , wherein the substituted C-Calkyl is —CHCHCHOCH.19. The method of claim 15 , wherein the substituted or unsubstituted carbocyclyl is a 6-membered ring.20. The method of claim 19 , wherein the substituted or unsubstituted 6-membered ring is a substituted or unsubstituted cyclohexyl.21. (canceled)22. The method of claim 1 , wherein Ris hydrogen and Ris hydroxyl.23. The method of claim 1 , wherein Rand Rform an oxo.24. The method of claim 1 , wherein Ris hydrogen.25. The method of claim 1 , wherein Ris methyl.26. (canceled)27. ( ...

Подробнее
20-02-2014 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20140051724A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее
27-02-2014 дата публикации

METHODS AND COMPOSITIONS FOR TREATING BIOFILMS

Номер: US20140056951A1

Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described. 2. The method of claim 1 , wherein the polyamine has Formula (IIa) claim 1 ,{'br': None, 'sub': 2', 'x', '2, 'HN-(M-NH)-M-NH\u2003\u2003(IIa).'}4. The method claim 1 , wherein the composition is administered to a surface of the subject selected from the group of dermal and mucosal surfaces and combinations thereof.5. The method of any of claim 1 , wherein the biofilm-related disorder is selected from the group consisting of pneumonia claim 1 , cystic fibrosis claim 1 , otitis media claim 1 , chronic obstructive pulmonary disease claim 1 , and a urinary tract infection and combinations thereof.8. The method of claim 7 , wherein the polyamine has Formula (IIa) claim 7 ,{'br': None, 'sub': 2', 'x', '2, 'HN-(M-NH)-M-NH\u2003\u2003(IIa).'}10. The method claim 7 , wherein the surface comprises a medical device claim 7 , a wound dressing claim 7 , a contact lens claim 7 , or an oral device.12. The method of claim 7 , wherein the composition further comprises a D-amino acid claim 7 , or pharmaceutically acceptable salts claim 7 , esters claim 7 , or derivatives thereof.13. The method of claim 12 ,wherein the composition comprises a combination of two or more D-amino acids selected from the group consisting of D-alanine, D-cysteine, D-aspartic acid, D-glutamic acid, D-phenylalanine, D-histidine, D-isoleucine, D-lysine, D-leucine, D-methionine, D-asparagine, D-proline, D-glutamine, D-arginine, D-serine, D-threonine, D-valine, D-tryptophan, D-asparagine, and D-tyrosine.15. The composition of claim 14 , wherein the polyamine has Formula (IIa) claim 14 ,{'br': None, 'sub': 2', 'x', '2, 'HN-(M-NH)-M-NH\u2003\u2003(IIa).'}18. A biofilm resistant medical device claim 14 , comprising:{'claim-ref': {'@idref': 'CLM-00014', 'claim 14'}, 'a surface likely to contact a biological fluid, said surface comprising a composition of coated on or ...

Подробнее
27-02-2014 дата публикации

METHODS AND COATINGS FOR TREATING BIOFILMS

Номер: US20140056952A1

Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described. 2. The method of claim 1 , wherein the polyamine has Formula (IIa) claim 1 ,{'br': None, 'sub': 2', 'x', '2, 'HN-(M-NH)-M-NH\u2003\u2003(IIa).'}5. The method of claim 1 , wherein the composition further comprises an effective amount of a D-amino acid claim 1 , thereby treating claim 1 , reducing or inhibiting formation of the biofilm.6. The method of claim 5 , wherein the D-amino acid is selected from the group consisting of D-alanine claim 5 , D-cysteine claim 5 , D-aspartic acid claim 5 , D-glutamic acid claim 5 , D-histidine claim 5 , D-isoleucine claim 5 , D-lysine claim 5 , D-leucine claim 5 , D-asparagine claim 5 , D-proline claim 5 , D-glutamine claim 5 , D-arginine claim 5 , D-serine claim 5 , D-threonine claim 5 , D-valine claim 5 , D-tryptophan claim 5 , D-tyrosine claim 5 , and combinations thereof.7. The method of claim 1 , wherein the article is one or more selected from the group consisting of comprises a industrial equipment claim 1 , plumbing systems claim 1 , bodies of water claim 1 , household surfaces claim 1 , textiles and paper.8. The method of claim 1 , wherein the article is made from a material selected from the group consisting of metal claim 1 , metal alloy claim 1 , synthetic polymer claim 1 , natural polymer claim 1 , ceramic claim 1 , wood claim 1 , glass claim 1 , leather claim 1 , paper claim 1 , fabric claim 1 , non-metallic inorganics claim 1 , composite materials and combinations thereof.9. The method of claim 1 , wherein contacting comprises applying a coating to the article claim 1 , said coating comprising an effective amount of the polyamine.10. The method of claim 9 , wherein the coating further comprises a binder.11. The method of claim 1 , wherein contacting comprises introducing a polyamine into a precursor material and processing the precursor material into the article impregnated ...

Подробнее
27-02-2014 дата публикации

Therapeutic polyamine compositions and their synthesis

Номер: US20140057877A1
Принадлежит:

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be utilized to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure. 1. A method of treating degenerative diseases due to acquired mitochondrial DNA damage , redox damage to mitochondrial macromolecules and inherited mitochondrial genetic defects said method comprising the steps of:selecting a composition from a group consisting of predominantly linear tetraamines and polyamines linked by 1,3-propylene and/or ethylene groups, predominately branched tetraamines and polyamines linked by 1,3-propylene and/or ethylene groups, cyclic polyamines linked by 1,3-propylene and/or ethylene groups, combinations of linear, branched and cyclic polyamines linked by one or more 1,3-propylene and/or ethylene groups, substituted polyamines, polyamines derivatized to form tyrosine phosphatase inhibitor molecules with linear or branched chains attached, polyamine derivatives of 2,2′-diaminobiphenyl with linear or branched chains ...

Подробнее
27-02-2014 дата публикации

POLYAMINE TRANSPORTER SELECTIVE COMPOUNDS AS ANTI CANCER AGENTS

Номер: US20140057989A1
Автор: IV Otto, Phanstiel

Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters. 1. A method of treating a cell , the method comprising contacting the cell with a compound or conjugate selected from compounds 4 , 7 , 10 , 15 , combinations thereof and their pharmaceutically acceptable salts.2. The method of claim 1 , wherein the cell treated is a cancer cell.3. The method of claim 1 , wherein the cell treated expresses an increased level of topoisomerase Ila and the compound claim 1 , conjugate claim 1 , combination or pharmaceutically acceptable salt selected comprises compound 4.4. The method of claim 1 , wherein the cell treated expresses a polyamine transport system and the compound claim 1 , conjugate claim 1 , combination or pharmaceutically acceptable salt selected comprises compound 15.5. The method of claim 4 , wherein compound 15 is used in an effective amount to at least partially inhibit the polyamine transport system of the cell. This application is a divisional of U.S. Ser. No. 12/113,540 filed May 1, 2008 and further claims priority to provisional application Ser. No. 60/915,448 filed on May 2, 2007, which are incorporated herein by reference in their entirety.The present invention relates to the field of cancer treatment and, more particularly, to polyamines which, due to their special structure, preferentially enter cells having an upregulated polyamine transport system.Polyamines are essential growth factors for cells. All cells have methods of manufacturing polyamines from aminoacid sources. In addition cells can import polyamines ...

Подробнее